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3SUMMARY
As mouse embryonic stem (ES) cells can be propagated in vitro in unlimited 
quantities and manipulated to generate homogenous populations of progenitor 
cells, they represent an attractive system to investigate questions that have been 
difficult to study in the developing mammalian nervous system. Here, we tested 
the differentiation potential of ES cell-derived progenitors that have the identity of 
radial glial (RG) cells, a population of cells that produce large numbers of 
neurons in the embryonic central nervous system of vertebrates. We implanted 
these cells into the neural tube of the chick embryo and examined their fate days 
later. The results indicate that the developmental potential of RG cells is 
restricted and they can only generate cell types that are expected from their 
developmental history. 
Since ES cells are accessible for genetic manipulations, we also investigated the 
role of molecules involved in neuronal development in genetically-modified ES 
cell-derived neurons. Specifically, we tested the effects of preventing the down-
regulation of the receptor for neurotrophins p75NTR during neuronal 
differentiation. This maneuver led first to the degeneration of all the neuronal 
processes (axons and dendrites), and to the later demise of the neuronal cell 
bodies. We found that the degeneration of these different neuronal 
compartments depends on distinct molecular mechanisms. In addition, we 
identified the endogenous lectin Galectin-1 as a player in the degeneration of 
neurons. Our results suggest that Galectin-1 acts as an effector of neuronal 
degeneration downstream of p75NTR, both in vitro and in vivo. Together, the 
experiments presented here illustrate the advantages of working with 
homogenous cell populations derived from ES cells.
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81. INTRODUCTION
1.1) Origin and characteristics of mouse ES cells
Following fertilization of a mouse egg, the newly formed diploid nucleus starts 
replicating and the egg is repeatedly cleaved, resulting in a rapidly growing cell 
aggregate generating two recognizable structures, the trophectoderm and the 
inner cell mass. The trophectoderm will become the placenta and the inner cell 
mass gives rise to the hypoblast and epiblast. The hypoblast in turn produces the 
yolk sac, which provides nutritional support to the embryo, while the epiblast 
gives rise to the embryo proper (Fig.1). Following gastrulation, the three primary 
germ layers –mesoderm, endoderm and ectoderm– are formed, from which all 
tissues of the body later arise. Early observations reported that embryos 
transplanted into adult mice readily generated teratocarcinomas, which are 
malignant tumors containing both differentiated and undifferentiated cells (Solter 
et al, 1970). Cells isolated from the undifferentiated fraction of teratocarcinomas 
exhibit extensive self-renewal in vitro and are also able to differentiate into cell 
types of all three primary germ layers. These cells are referred to as embryonic 
carcinoma (EC) cells, and it was established that they originate from the 
embryonic epiblast, since they cannot be isolated from teratocarcinomas derived 
from embryos that had already undergone gastrulation (for review see Smith, 
2002). The differentiation of EC cells into mature cell types is however not 
frequent, and instead they readily form tumors. Moreover, if re-introduced into a 
blastocyst, EC cells can not contribute to the germ-lineage of chimeric mice and 
are therefore incapable of producing germ-line transmission, indicating that their 
developmental potential is limited. Nevertheless, these early results with EC cells 
suggested that cells with self-renewal and differentiation potential exist in the 
early embryo, and promoted the search for embryo-derived stem cells with larger 
developmental potentials. 
An important realization was that culturing EC cells in the presence of mitotically 
inactivated mouse embryonic fibroblast (MEFs) improves both, their self-renewal 
and differentiation (Martin and Evans, 1975). One cell line isolated directly from 
9blastocyst-stage (pre-gastrulaiton) embryos exhibited similar self-renewal 
characteristics to EC cells and was referred to as embryonic stem (ES) cells 
(Evans and Kaufman, 1981; Martin, 1981). Specifically, ES cells were isolated 
from the inner cell mass of the blastocyst by gentle dissociation, and then seeded 
onto MEFs. Like EC cells, ES cells divide rapidly and form colonies that can be 
easily distinguished by their morphology, which resembles a tightly packed 
potatoes-like structure. When these colonies were dissociated and re-platted 
onto inactive MEFs, individual clones generated ES cell colonies with the same 
morphology. By repeating this procedure, ES cells could be passed for unlimited 
times while retaining their undifferentiated state, and without signs of senescence 
such as telomere shortening (Smith, 2001). 
When ES cells are cultured in the absence of MEFs and without added serum or 
growth factors, they rapidly start differentiating, suggesting that the maintenance 
of self-renewal is controlled by extrinsic factors. Notably, the differentiation-
inhibiting activity of MEFs can be substituted by the cytokine leukemia inhibitory 
factor (LIF) (Smith et al, 1992; Williams, 1988). In the presence of ES cells, 
MEFs themselves produce LIF in substantial quantities (Rathjen et al, 1990), and 
MEFs deficient for the LIF gene cannot maintain ES cell self-renewal (Stewart et 
al, 1997). LIF binds to the gp130 receptor, which is expressed by mouse ES cells 
and is known to activate the intracellular JAK/STAT3 signaling pathway (Burdon 
et al, 1999). More recently, other factors in addition to LIF were shown to 
contribute to the maintenance of ES cell self-renewal. These include members of 
the BMP (Ying et al, 2003) and the Wnt families (Sato et al, 2004). While LIF 
signaling engages STAT3, BMP signaling engages as intracellular mediators the 
Id and Smad proteins, and Wnt signaling engages ?-catenin and GSK-3.
What remains to be further investigated is how LIF, BMPs and Wnts, control 
intrinsic molecular determinants of self-renewal. The transcription factors Oct3/4 
and Nanog were shown to be required for maintaining the undifferentiated state 
of ES cells (Shimozaki et al, 2003; Minucci et al, 1996; Niwa et al, 2002). Oct3/4-
and Nanog- deficient ES cells are not capable of extensive self-renewal and 
spontaneously differentiate, even in the presence of LIF. It is likely then that LIF, 
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BMPs and Wnts, exert their effect on ES cells by controlling the expression and 
activity of transcription factors such as Oct3/4 and Nanog. 
In addition to self-renewal under defined conditions, ES cells posses a 
remarkable differentiation potential. This is best demonstrated by experiments 
showing that when ES cells are re-introduced into mouse blastocysts, they 
contribute cells to tissues of all three primary germ layers, including the germ cell 
lineage of chimeric animals. More remarkably, the cells contributed to the germ 
cell lineage are often functional and can generate germ line transmission 
(Bradley et al, 1984). These attributes of ES cells, in combination with the ease 
of their genetic manipulation, have made possible the engineering of genetically 
modified mice carrying for example, deletions of specific genes (Capecchi, 1989). 
Based on these studies, ES cells are defined as pluripotent stem cells, as they 
can contribute to all cell types of the body.
While there is no question that ES cells are remarkably useful, it remains open if 
these cells really exist in vivo, or if they are an in vitro artifact made possible by 
the use of special culture conditions. Since ES cells are normally isolated from 
the epiblast, and this is a transient embryonic structure, one would expect that 
ES cells do not self-renew for too long, but instead differentiate into the cells of 
the three primary germ layers. One possibility is that epiblast cells have evolved 
mechanisms to delay their differentiation if development is for any reason halted. 
If this were the case, then the cells would self-renew without differentiating until 
development re-starts. Experimental evidence supporting this idea exists. The 
LIF and gp130 genes are expressed in pre-gastrula embryos, and while removal 
of either gene does not cause overt phenotypes before gastrulation, it severely 
affects the maintenance of the epiblast during diapause (Nichols et al, 2001). The 
term diapause refers to a period during which the normal implantation of a 
blastocyst is delayed by 3-4 weeks, and during which epiblast cells are prevented 
from differentiating. Furthermore, isolation of ES cells from diapause-stage 
blastocysts is more efficient than from normal blastocysts (Gardner and Brook, 
1997). Therefore, in vitro self-renewing ES cells may resemble epiblast cells in 
diapause blastocysts in vivo, and the use of differentiation-inhibiting factors such 
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as LIF may thus represent a natural mechanism for the maintenance of their 
undifferentiated state. 
1.2) ES cells versus adult stem cells 
Most tissues posses a certain number of stem cells, which are responsible for 
producing all mature cell types of the tissue where they reside. These cells are 
thus referred to as tissue stem cells or somatic stem cells. For example, 
hematopoietic stem cells continue to replenish all types of blood cells, including 
red blood cells, lymphocytes and macrophages. Mesenchymal stem cells 
produce cells of the bone, cartilage and muscle. Epidermal stem cells generate 
keratinocytes of the skin, and epithelial stem cells contribute different cell types in 
the lining of digestive tracts. In addition, somatic stem cells can be recruited by 
injury and they play an important role on tissue repair (for review see Rando, 
2006). Stem cells have also been described in the adult nervous system. About 
40 years ago it was observed that the adult mammalian brain exhibited active cell 
division in restricted regions (Altman, 1965). It was later shown that two regions 
contained neural stem cells, the subventricular zone (SVZ) of the lateral ventricle 
and the dentate gyrus of the hippocampus. SVZ stem cells generate neuroblasts 
that migrate towards the olfactory bulb to become inhibitory neurons. Neural 
stem cells in the dentate gyrus of the hippocampus generate granule cells that 
integrate within the local environment (for review see Gage, 2002). 
While the extent of neurogenesis in the adult brain of rodents is somehow limited 
and its function is still under heavy investigation, work with songbirds 
demonstrated a remarkable physiological relevance. In some of these species, 
the capacity to learn new songs varies during adult life, and this correlates with 
the addition of new neurons in specific regions (Goldman and Nottebohm, 1983; 
Nottebohm, 1981). Interestingly, newly-generated neurons are short-lived, being 
used for learning of single songs and then discarded.
Early work by Reynolds and Weiss (1992) set out to isolate stem cells from the 
neurorogenic regions of the rodent brain. When the SVZ or dentate gyrus are 
dissociated and the cells are seeded without substrate, they form floating 
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aggregates that are reffered to as neurospheres (Reynolds and Weiss, 1992). 
These aggregates grow when the growth factors bFGF and EFG are added. If 
dissociated and re-seeded at clonal density under the same conditions, some of 
the cells can give rise to new neurospheres. When mitogens are removed, some 
of the cells within neurospheres differentiate and can produce astrocytes, 
oligodendrocytes and neurons (Reynolds and Weiss, 1992). Therefore, 
neurospheres are typically said to contain neural stem cells.
Given the interesting prospect of using neural stem cells for tissue repair, studies 
tested the differentiation potential of neurosphere-derived cells after 
transplantation in vivo. There, cells are confronted with signals pushing them into 
adopting different phenotypes. Interestingly, some of these studies suggested 
that neural stem cells posses a rather broad differentiation potential and can 
generate not only cells from the tissue where they reside, but also cells from 
other regions (for review see Frisen, 2002). For example, adult hippocampal 
stem cells transplanted into the hippocampus generated interneurons as 
expected, but when transplanted into other brain regions they could generate 
olfactory bulb neurons, retinal neurons and cerebellar cells (Suhonen et al, 1996; 
Takahashi et al, 1998). An even greater differentiation potential was ascribed to 
neural stem cells by studies claiming that these cells crossed lineage barriers to 
generate non-neural cell types. Two reports indicated that transplanted neural 
stem cells could differentiate into muscle cells (Galli et al, 2000) and into blood 
cells (Bjornson et al, 1999). Furthermore, Clarke et al (2000) suggested that 
neural stem cells transplanted into young embryos could also differentiate into 
cells of all primary germ layers. These studies however, need to be taken with 
caution for several reasons. First, the ex vivo expansion with growth factors prior 
to transplantation can affect the differentiation potential of cells in ways that they 
would not necessarily correspond to what stem cells do in vivo (for review see 
Anderson, 2001). For instance, when cultured with growth factors, 
oligodendrocytes can be “re-programmed” and generate neurons (Kondo et al, 
2000). Furthermore, neurospheres typically contain a very heterogenous 
population of cells (Suslov et al, 2002), and the identity of the SVZ and 
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hippocampal stem cells has not been fully characterized yet. In addition, studies 
found that stem cells can also fuse with other cells (Ying et al, 2002), suggesting 
that some of the previous studies claiming that stem cells could cross lineage 
barriers might have been the result of stem cell fusion with the host cells (for 
review see Wurmser and Gage, 2002). Therefore, it remains difficult at present to 
precisely define the developmental potential of adult neural stem cells. In 
contrast to neural stem cells, ES cells do not seem to change their properties 
after long term expansion in vitro. In addition, the pluripotency of ES cells is 
hardly disputed, as the existence of ES cell-derived mice demonstrates their 
potential to produce all cell types of the body.
1.3) In vitro differentiation of ES cells into the neural lineage
An important aspect of ES cell biology is that upon removal of LIF, ES cells 
rapidly loose their undifferentiated state and start differentiating. Since ES cells 
are pluripotent when re-introduced in vivo, the possibility exists to direct ES cell 
differentiation into defined cell types in vitro by culture with a variety of pro-
differentiation factors. Protocols were thus developed to obtain different cell types 
from ES cells, including for example cells of the skin, gut, immune system, bone, 
connective tissue and muscle (for reviews see Guan et al, 2001; Wobus and 
Boheler, 1999). Interestingly, when cultured without LIF and at very low density, 
some ES cells spontaneously differentiate into neurons (Ying et al, 2003). 
Because only low levels of neural differentiation are found during spontaneous 
differentiation of ES cells (Strübing et al, 1995; Schmidt et al, 2001), procedures 
to enhance their neurogenic potential were developed. Importantly, the ability of 
ES cells to differentiate into different cell types is enhanced when cultured 
without adhesive substrate. There, ES cells rapidly form cell aggregates referred 
to as embryoid bodies (EBs). EBs can be produced by ES cells even at clonal 
density and after 2-6 days of culture in the presence of LIF, they consist of 
thousands of undifferentiated ES cells. 
Among the extracellular signals known to direct the differentiation of both EC 
cells and ES cells towards neurogenesis, retinoic acid (RA) has been particularly 
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successful (Rohwedel et al, 1999; Bain et al., 1995; Renoncourt et al, 1998; Li et 
al, 1998; Aubert et al, 2002). Retinoic acid is a low molecular weight (300 Da) 
lipophilic molecule and the biologically active metabolite of Vitamin A. Retinoic 
acid binds to cytosolic RA receptors, which then dimerize and activate RA-
responsive genes in the nucleus. Studies reported that the addition of RA to ES 
cell aggregates directs their differentiation into the neural lineage, and when 
dissociated, some of the cells produce neurons (Bain et al., 1995; Okabe et al., 
1996; Renoncourt et al, 1998; Li et al, 1998; Wichterle et al, 2002). However, 
most of these protocols lead to rather heterogeneous cell populations. For 
example, RT-PCR performed on RA-treated ES cells revealed the presence of 
transcripts for Trk receptors, Glutamic acid decarboxylase, Tyrosine hydroxylase
and Hb9, which are genes expressed by different classes of mature neurons in 
the nervous system (Renoncourt et al, 1998). Immunostaining of ES cell 
aggregates showed cells expressing markers typical of neural progenitors such 
as Nestin, Pax6 and Pax7, and also of pan-neuronal markers like MAP2 and NF-
145 (Renoncourt et al, 1998). More recently, Wichterle et al (2002) showed that 
motoneurons can be produced by treatment of ES cell aggregates with RA and 
sonic hedgehog, a molecule known to promote motoneuron differentiation in vivo 
(Roelink et al, 1995). This study was important as it showed that the difrentiation 
of ES cells can be directed into specific neuronal types. However, motoneurons 
constituted a small fraction of the cells within the aggregates, and FACS sorting 
was used to purify motoneurons from the rest of the cells (Wichterle et al, 2002). 
Other studies also employed methods for purifying the desired cells. One 
approach is the use ES cell lines carrying resistance cDNAs under the control of 
lineage-specific promoters, which are cultured with selection drugs (Klug et al, 
1996; Li et al, 1998). Another alternative is the use of ES cells constitutively 
expressing transcription factors known to induce differentiation into specific 
neuronal types. For example, over-expression of the transcription factor Nurr1 in 
ES cells can enhance their differentiation into dopaminergic neurons (Kim et al, 
2002). However, it remains unclear whether homogenous populations of 
progenitor cells and of neurons can be obtained using ES cell aggregates. This is 
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of importance since at present, obtaining large quantities of neurons by direct 
isolation from animals remains difficult. Moreover, the purity and homogeneity of 
the primary neuronal cultures typically established are not consistently 
satisfactory. Contamination with large numbers of non-neuronal cells and/or with 
different types of neurons troubles the analysis of results obtained for example, 
from gene or protein expression comparisons. 
Recently, our laboratory established a new ES cell-based method leading to 
unlimited numbers of highly pure and homogenous neuronal cultures (Bibel et al, 
2004). Briefly, ES cells are expanded first with and then without MEFs in the 
presence of LIF. Importantly, we now understand that special care has to be 
taken to select ES cells cultures where all ES cells exhibit an undifferentiated 
morphology, typically evidenced by a high nucleus/cytoplasm area ratio as well 
as by very salient nucleoli. In addition, only ES cell cultures that divide rapidly are 
used, as a high rate of cell division is essential for the subsequent differentiation 
into neural progenitors. ES cell aggregates are then formed and cultured for 8 
days without LIF. In these aggregates, ES cells continue proliferating and the 
aggregates grow in size until the fourth day, when proliferation is balanced by 
extensive cell death. The aggregates are then exposed to RA for the last four 
days, and when gently dissociated and plated on poliornithine/laminin, the large 
majority of the cells develop into post-mitotic neurons within ~36 hours. Notably, 
the neurons have the antigenic profile of glutamatergic neurons isolated from the 
developing cerebral cortex. They express the glutamate transporter vGLUT-1, 
the receptors for neurotrophins TrkB and p75NTR and the amyloid precursor 
protein (APP). In addition, their electrophysiological characteristics are similar to 
those of glutamatergic cortical neurons. Interestingly, after plating the cells 
express the markers Pax6, BLBP and RC2. These markers are normally 
expressed during development by a population of cells in the neural tube called 
radial glial (RG) cells.  
1.4) RG cells as neural progenitors
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In vertebrates, RG cells are the first cell type that can be distinguished from 
neuroepithelial cells throughout the neural tube. They share some characteristics 
with neuroepithelial cells and also with mature astrocytes. Like neuroepithelial 
cells, they express the intermediate fillemant Nestin, the marker RC2 (likely to be 
a modified form of Nestin), and they have a bipolar morphology. Like astrocytes, 
they have glycogen granules and they express the glutamate transporter GLAST, 
the BLBP protein, and the intermediate filament GFAP (only in primates and 
adult rodents) (for review see Kriegstein and Gotz, 2003). Some RG cells also 
express the transcription factors Sox2 and Pax6 (see Discussion). It has 
traditionally been considered that the role of RG cells is to guide the migration of 
newly born neurons along their radial processes and to differentiate into 
astrocytes later in development (Rakic, 2003). However, recent work 
demonstrated that RG cells also generate neurons (Malatesta et al, 2000). 
Indeed, RG cells produce most of the pyramidal neurons in the developing dorsal 
telencephalon as well as many neurons in the spinal cord (Malatesta et al., 
2003). Furthermore, there is increasing evidence suggesting that the cells that 
act as neural stem cells in the adult brain posses the characteristics of RG cells. 
Studies by Doescht et al (1999, 2003) first showed that cells belonging to the 
astroglial lineage acted as neural stem cells in the SVZ and the dentate gyrus 
(REF and see discussion). Cells in these regions express GFAP, and cell fate 
mapping experiments recently confirmed that these GFAP-expressing cells are 
the source of adult neurogenesis (Garcia et al, 2004). Moreover, the genetic 
ablation of GFAP-expressing cells dramatically decreased adult neurogenesis 
(Garcia et al, 2004). The same conclusion was also reached by another study 
using a virus-mediated cell fate mapping approach (Merkle et al, 2004). 
Interestingly, in several non-mammalian vertebrates RG cells are retained 
throughout life in their CNS. These animals are capable of extensively 
regenerating their adult CNS after lesion (for review see Doetsch, 2003), 
highlighting the potential use of RG cells for cell replacement therapies. 
Together, these studies show that RG cells play a major role as progenitors for 
neurons, both in the embryo as well as in the adult CNS. Therefore, it would be 
17
of interest to test how broad the developmental potential of RG cells is, by for 
example, introducing these cells into an in vivo environment. Direct isolation of 
RG cells has been reported using transgenic mice in which the human GFAP
promoter drives expression of GFP in RG cells, allowing these cells to be FACS-
sorted (Malatesta et al, 2000). However, it remains difficult to obtain large 
numbers of homogenous RG cells using this approach. Given the generation of 
uniform RG cells from ES cells (Bibel et al, 2004), we thus set out to compare our 
ES cell-derived progenitors to in vivo-existing RG cells, and to test their 
developmental potential by implanting them into the nervous system of chick 
embryos. The results of these experiments are presented in section 2.1 and 
discussed in section 3.1 of this Thesis. 
1.5) The neurotrophin receptor p75NTR
In the second part of this Thesis (sections 2.2 and 3.2), we illustrate another use 
of ES cells to study mechanisms related to neural development. As in vivo over-
expression of the neurotrohin receptor p75NTR is known to cause neuronal 
degeneration in the developing nervous system, we engineered ES cells to 
prevent the down-regulation of this receptor during neuronal differentiation. 
p75NTR is a single pass transmembrane glycoprotein that belongs to the TNF 
receptor superfamily (for review see Dechant and Barde, 2002). It has a death 
domain in its intracellular region (conserved among TNF receptor superfamily 
members), and four consecutive extracellular cystein-reach domains. p75NTR is 
expressed mostly in the developing nervous system by a large number of 
neurons, especially those extending long axons. In the adult nervous system, 
p75NTR expression is down-regulated in almost all neurons, with the exception of 
for example cholinergic neurons of the basal forebrain. In addition, a large 
number of neurons express p75NTR in primary cultures, including sensory, 
sympathetic, hippocampal and cortical neurons. Like is the case in vivo, these 
cells also down-regulate p75NTR expression as they mature in vitro. p75NTR binds 
to all the mammalian neurotrophins (NGF, BDNF, NT3 and NT4), and ligand 
binding leads to different outcomes, depending on the cellular context. Since 
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p75NTR lacks an intrinsic catalytic activity, it activates signaling by recruiting 
different intracellular interactors. It is generally thought that signaling via p75NTR
leads to negative cell behaviours including cell death and inhibition of axonal 
elongation. For example, NGF acting via p75NTR induces programmed cell death 
in olygodendrocytes and in retinal ganglion cells (Frade and Barde, 1996; 
Cassacia-Bonnefil et al, 1996). p75NTR null mice exhibit decreased apoptosis in 
the developing retina, spinal cord and sympathetic system (Frade and Barde, 
1999; Bamji et al, 1998), and increased numbers cholinergic neurons in their 
adult basal forebrain (Naumann et al, 2002). In transgenic mice, over-expression 
of the intracellular domain of p75NTR using a neuronal-specific tubulin promoter 
leads to widespread decrease in neuronal numbers throughout the nervous 
system (Majdan et al, 1997).
p75NTR also acts as a negative regulator of axonal elongation by activating the 
small GTPase RhoA, and defects in the growth of spinal nerves (Yamashita et al, 
1999) and in spine numbers (Zagrebleski et al, 2005), were reported in p75NTR
mutants. Also in cultured retinal ganglion neurons, p75NTR-activation of RhoA 
restricts the elongation of fillopodia (Gehler et al, 2004). In addition to Trk 
receptors, p75NTR also interacts with the Nogo receptor and LINGO (for review 
see Gentry et al, 2004), and together these proteins mediate the inhibitory effects 
of various myelin-associated proteins. 
ES cell-derived neurons also express p75NTR in our system (Bibel et al, 2004). 
Like is the case for neurons in vivo, the expression of p75NTR is down-regulated 
in ES cell-derived neurons in the first days after plating of the progenitors (Bibel 
et al, 2004). Here, we engineered ES cells to express a cDNA for p75NTR from an 
endogenous neuronal-specific promoter. We differentiated these cells in vitro and 
found that this can be used as a new model system to study neuronal 
degeneration.
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2. RESULTS
2.1) IN VIVO IMPLANTATION OF ES-CELL DERIVED 
PROGENITORS 
2.1.1) Antigenic characterization of RA-treated ES cells  
The goal of this set of experiments was to test the differentiation potential of 
homogenous populations of ES cell-derived neural progenitors. We used mouse 
ES cells pre-differentiated in vitro as described in Bibel et al (2004) and 
implanted them into the neural tube of chick embryos. Briefly, ES cells were 
cultured in non-adhesive dishes where they formed aggregates. After four days 
of treatment with RA we fixed and cryo-sectioned aggregates for 
immunostaining. The majority of the cells within the aggregates expressed 
several RG markers. These included the intermediate filament Nestin, the 
transcription factor Sox2, the RG marker RC2, the glutamate cell membrane 
transporter GLAST, and the homeodomain transcription factor Pax6 (Fig.2). Cells 
expressing these markers were evenly distributed throughout the aggregates. 
RA-treated aggregates did not contain cells expressing the markers Pax7 or 
Nkx2.2, which in the neural tube define progenitors located at more dorsal and 
ventral positions, respectively, of Pax6-positive cells (Ericson et al, 1997). Less 
than 1% of the cells in RA-treated aggregates expressed Lim1/2, Hb9 
(recognized by the anti-MNR2 chick antibody), Isl1 or Olig2, which are markers 
normally expressed by differentiating neuronal precursors in the spinal cord and 
in the DRG. Also, no cells were positive for the sensory marker Brn3a (data not 
shown). The majority of the cells within RA-treated aggregates were found to still 
divide rapidly after 4 days, as assessed by a 3 hour pulse of BrdU prior to fixation 
(Fig. 2). ES cells in aggregates that were not treated with RA failed to express 
any of the markers mentioned in the above (data not shown). Instead, they 
expressed the transcription factor Oct3/4, indicating their pluripotent and 
undifferentiated state (Fig.6A). Taken together, these observations indicate that 
RA-treated ES cell aggregates contain a uniform population of progenitors with 
20
the antigenic characteristics of RG cells found in developing neural tube (for 
reviewed see Kriegstein and Gotz, 2003).  
2.1.2) Differentiation of RA-treated ES cell aggregates in the chick neural 
tube
To evaluate the differentiation potential of RA-treated ES cells, we partially 
trypsinised single aggregates and implanted them into the caudal CNS of stage 
13-14 (E2) chick embryos in ovo. At these developmental stages the chick neural 
tube has just closed, neural crest cells started to migrate towards the periphery 
and the presomitic mesoderm adjacent to the neural tube differentiated into 
somites.
To follow their neuronal differentiation in ovo, we used for all the experiments a 
line of ES cells that had both tau alleles targeted with GFP (Bibel et al, 2004). 
Work from our laboratory has previously shown that the endogenous tau
promoter drives expression of GFP soon, and long after cells become post-
mitotic neurons (Tucker et al, 2001). In order to accommodate foreign cells, one 
neural fold was completely removed for 4 somites in length at level of the 
forelimb bud (somites 17 to 20) prior to transplantation (Fig.3A). The implanted 
cells occupied the slot made by the surgery. The eggs where then sealed and 
incubated for a further 6 days until E8, which is the time when all neuronal types 
have differentiated in the chick spinal cord. Embryos surviving the operation 
(Table 1) were removed from the egg and observed under a fluorescent 
microscope. A GFP signal found at the implant region indicated that the donor 
cells survived and differentiated into neurons in the chick host (see Table 1). 
Serial transverse sections were then analyzed and stained with the nuclear stain 
Hoechst, allowing mouse and chick cells to be unambiguously identified on the 
basis of their distinct nuclear morphologies (Fontaine-Perus et al., 1997 and Fig. 
3B). Mouse neurons expressing GFP were detected in all consecutive sections of 
the implant area. Notably, the operated side of the spinal cord was extensively 
populated by mouse neurons and it closely resembled the adjacent non-operated 
side in size and morphology (Fig.3). Also, a bundle of GFP+ axons were often 
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observed projecting from the ventral spinal cord towards the periphery, 
resembling a ventral root (Fig. 3 and Table 1). Cell counts revealed that the 
majority of the nuclei exhibiting mouse morphology co-localized to GFP-
expressing cells (see Table 2), indicating that the majority of the donor cells 
differentiated into post-mitotic neurons. Together, these observations show that 
donor cells survive in very large numbers for prolonged periods of time, and that 
they differentiate mostly into neurons in the chick spinal cord.  
In the spinal cord, specific types of interneurons and motoneurons are generated 
from a pool of progenitor cells expressing markers that we also find in our RA-
treated ES cells (Ericson et al., 1997; Graham et al., 2003; and also see scheme 
in Fig.4). Endogenous progenitor cells co-expressing Nestin, RC2, Sox2 and 
Pax6 are distributed in the central region of the neural tube that can be 
delineated by two borders, a Pax7+/Pax6- region lying dorsal to it, and a 
Nkx2.2+/Pax6- region lying ventral to it. Pax6+ progenitors generate interneurons 
that are located throughout the entire dorsal-ventral part of the central region of 
the spinal cord (Ericson et al, 1997). Some of these inhibitory neurons elongate 
axons ventrally that input into ventrally-located motoneurons to modulate motor 
activity, while others reach the ventral part of the spinal cord, cross the midline, 
and then project anteriorly through the white matter and towards higher central 
regions. Both of these interneuron subtypes can be recognized by the expression 
of the homeodomain transcription factor Lim1/2 (Ericson et al, 1997). Pax6+ 
progenitors also generate spinal cord motoneurons. These neurons have a larger 
cell body size than interneurons and are located ventrally with the exception of 
those occupying the column of Terni, that are located in the central region. 
Motoneurons express the transcription factors Hb9 and Isl1 and project their 
axons from the ventral spinal cord through the ventral roots into the periphery, 
where they bundle with sensory DRG axons to form spinal nerves (Wichterle et 
al, 2003). 
We next asked whether the implanted progenitors had acquired these cell fates 
in vivo. GFP-expressing neurons were found located throughout the central 
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region of the spinal cord expressing the interneuron marker Lim1/2 and 
projecting axons ventrally (Fig.4A and Table 3). Ventrally-located GFP+ neurons 
expressed the motoneuron markers Hb9 and Isl1 (Fig. 4B,C), and extended long 
GFP+ axons from the ventral spinal cord towards the periphery (Fig. 4B). These 
cells also had larger cell body sizes than the GFP+/Lim1/2+ neurons (data not 
shown). Importantly, GFP+/Lim1/2+ cells located dorsal to the motoneuron 
domain of the spinal cord did not express Hb9 (Fig. 4J-K'). 
We then examined the expression of neurotrophins receptors by donor cells. In 
the chick embryo, expression of p75NTR becomes detectable in the ventral spinal 
cord at E2 (McKay et al., 1996), and is still detectable in motoneurons when they 
extend axons (Yamamoto and Henderson, 1999). By contrast, expression of 
TrkB becomes detectable in the spinal cord throughout the gray matter and also 
in motoneurons and their axons at E8 (McKay et al., 1996). Both because of the 
functional role of neurotrophin receptors and their characteristic expression 
pattern, we explored whether donor neurons would express neurotrophin 
receptors. We found that donor neurons in the spinal cord expressed both p75NTR
and Trk receptors (Fig.4D-I).  Expression of p75NTR was detected in GFP+ 
neurons throughout the spinal cord and high levels of expression were detected 
in cells located to the ventral motorneuron domain, which extended GFP+/ 
p75NTR+ axons towards the periphery via the ventral root, in accord with their 
motoneuron identity. In constrast to p75NTR, Trk receptor expression was widely 
detected in GFP+ neurons located throughout the dorsal-ventral axis of the spinal 
cord as well as in GFP+ axons projecting towards the periphery. Together, these 
results indicate that RA-treated ES cell aggregates can generate interneurons 
and motoneurons in a time- and position-dependent fashion in the host spinal 
cord.
2.1.3) RA-treated ES cell aggregates populate dorsal root ganglia, but fail to 
express sensory neuron markers and to elongate axons
In the chick embryo, neural crest cells delaminate from the dorsal neural tube 
and start migrating to the periphery to form the PNS at E2 (Le Douarin and 
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Kalcheim, 1999). Neural crest cells are a highly multipotent, transient cell 
population. These cells generate not only the entire PNS, but they also contribute 
non-neural cells to a remarkably large number of tissues (Le Douarin and 
Kalcheim, 1999). The dorsal root ganglia (DRGs) are composed of neural crest-
derived sensory neurons that extend a bi-polar axon projecting both centrally 
through the dorsal horn of the spinal cord, as well as peripherally to innervate 
targets such as the muscle spindles. Since our progenitors were implanted at 
developmental stages when neural crest cells are migrating towards the DRG 
anlagen and starting to differentiate into sensory neurons, we examined if donor 
cells could also colonize the PNS. GFP-positive cells were frequently found in the 
host DRG (Fig.5A and Tables 1,2). However, unlike their chick counterparts in 
the DRG, mouse neurons never expressed the transcription factors Brn3a (Fig. 
5B) or Isl1 (Fig. 5C), which are markers that define most neurons in that structure 
(Anderson, 1999 and references therein). In addition, we never found mouse 
neurons elongating axons outside the DRG, even though GFP expression 
indicated their neuronal identity. These cells expressed p75NTR at high levels 
(Fig. 5D), but they failed to express detectable levels of Trk receptors (Fig. 5E). It 
thus appeared that while the donor cells can differentiate into neurons in the host 
DRG, they are incapable of adopting a more mature DRG neuron phenotype and 
to elongate axons.
2.1.4) RA-untreated ES cell aggregates generate both spinal cord and DRG 
neurons in vivo 
To test the pluripotent character of mouse ES cells in the chick embryo, we next 
implanted ES cells that were allowed to form aggregates for 36 hours in the 
presence of LIF and without RA, and subsequently implanted in the chick neural 
tube following the same procedure as described for RA-treated ES cells (Fig.3A). 
Prior to implantation, ES cells expressed the transcription factor Oct3/4 (Fig. 6A). 
Expression of this transcription factor is a reliable indication of the 
undifferentiated and pluripotent character of ES cells (Niwa et al, 2000; Boiani et 
al, 2002), and its expression is down-regulated when ES cells are deprived of LIF 
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(Fig.6A). RA-untreated ES cell  aggregates completely failed to express Nestin, 
Sox2, Pax6, Pax7, RC2, GLAST, Lim1/2, Hb9, Isl1, Nkx2.2, Olig2, and Brn3a 
(data not shown). Like RA-treated ES cells, RA-untreated ES cells also survived 
in large numbers and differentiated into neurons in the host spinal cord (see 
Tables 1, 2). Mouse GFP-positive neurons located throughout the spinal cord 
expressed Lim1/2 (Fig.6B), suggesting their differentiation into interneurons. 
Ventrally located mouse neurons expressed Hb9 and Isl1 (Fig.6C,D) and 
elongated long axons towards the periphery, suggesting that they differentiated 
into motoneurons. These cells also expressed Trk and p75NTR neurotrophin 
receptors in their cell bodies and in their axons (Fig.6E,F). Like the progeny of 
RA-treated cells in the spinal cord, donor cells located dorsal to the motoneuron 
domain did not express Hb9 (data not shown). 
Numerous GFP-positive neurons were also found in the DRG (Fig. 7A). Notably, 
these cells expressed Brn3a (Fig. 7C) as well as Isl1 (Fig. 7D), and they also 
elongated axons both towards the spinal cord and towards the periphery (Fig. 
7A,B,H; see Table 3 for a quantitative comparison with RA-treated cells). ES cell-
derived neurons expressed p75NTR (Fig. 7E), but in contrast to RA-treated cells in 
the DRG, they also expressed high levels of Trk receptors in their cell bodies and 
in their axons (Fig. 7F-H). Neither ES cells nor RA-treated cells ever expressed 
Hb9 (Fig. 7I) or Lim1/2 (Fig. 7J) when colonizing the DRG.Taken together, these 
results indicate that the failure of our ES cell-derived Pax6-positive progenitors to 
be fully responsive to chick derived development, is not due to a limitation of our 
implantation system. 
2.2) AN ES-CELL BASED MODEL OF NEURONAL 
DEGENERATION
2.2.1) Engineering of tau::p75NTR neurons 
Since our results showed that cells that failed to extend axons in the DRG 
expressed high levels of p75NTR, we were next interested to study the effects of 
this receptor on neuronal development using in vitro differentiation of ES cells. In 
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the ES cell-derived neurons obtained using our differentiation protocol, p75NTR is 
initially expressed at high levels (Bibel et al, 2004). But like is the case for many 
neurons in vivo, p75NTR is down-regulated as a function of neuronal maturation. 
To better understand the function of p75NTR in developing neuros, we designed a 
strategy to prevent its down-regulation as ES cell-derived neurons develop. A 
cDNA encoding rat p75NTR was targeted into the endogenous tau locus. These 
ES cells had their other tau allele previously targeted with GFP, as described in 
Bibel et al (2004). The tau gene is activated in all ES cells as soon as they 
become post-mitotic neurons, and GFP fluorescence starts to be visible ~24 
hours after platting (data not shown). The increase in the number of GFP+ cells 
is accompanied by a reduction in the number of cycling cells within the first two 
days after platting. Cumulative BrdU experiments in which BrdU was applied to 
cultures at different times after platting, and its incorporation into cycling cells 
assessed at day 4, revealed that 48.3% incorporate BrdU applied at day 2, 
31.2% at day 3 and 11.9 % at day 4 (data not shown). We next compared the 
differentiation of this ES cell line, hereafter referred to as tau::p75NTR, with a 
control line that had both tau alleles targeted with GFP (Bibel et al, 2004). 
2.2.2) Neuronal processes degenerate before cell bodies in tau::p75NTR
neurons
Both tau::p75NTR and control neurons initially extended processes (Fig.8A), but 
on the third day after differentiation the processes of tau::p75NTR neurons began 
to appear unhealthy as evidenced by the appearance of irregular swellings 
(Fig.8A,D), while the cell bodies remained indistinguishable from those in control 
cultures. By day 4, virtually all processes degenerated and became fragmented, 
while ever more branches developed in control cultures (Fig.8A,C). This 
morphological appearance is reminiscent of what has been observed with DRG 
neurons after axotomy or trophic factor deprivation of sympathetic neurons (Zhai
et al, 2003 and see Discussion). The earliest signs of degeneration were 
consistently detected in the more distal secondary branches which were always 
eliminated first. This was followed by the degeneration of principal processes 
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(those growing directly from the cell body; Fig.8D). By day 5, virtually all neuronal 
processes in the culture had completely degenerated and at this time point, the 
cell bodies began to exhibit typical features of apoptotic death. They developed 
swellings at the cell surface that were visible by phase contrast, and their nucleus 
started to acquire a pyknotic morphology (Fig.8D). 
We next examined the expression levels of p75NTR in our system. Western blots 
performed at day 2 revealed that tau::p75NTR cells express about 50% higher 
levels of p75NTR than control cultures (Fig.9A). 
To examine the localization of p75NTR, we stained non-permeabilised neurons 
with an antibody directed against the extracellular domain of p75NTR. We found 
that in both lines p75NTR was localized at the surface of cell bodies as well as 
along the processes, including the growth cones. Its distribution was not 
homogenous, but always appeared as clusters at the cell surface (Fig.9B). This 
pattern was confirmed by staining tau::p75NTR neurons with the monoclonal 
antibody MC192, which is directed against the extracellular domain of rat p75NTR
(data not shown). No positive staining was observed with neither of these 
antibodies in neurons carrying a full deletion of p75NTR (data not shown). We 
further tested whether the clustering of p75NTR was specific for this protein by 
comparing it with staining for other proteins known to be associated with the cell 
surface of neurons. We chose the transferin receptor and the glutamate receptor 
interacting protein-1(GRIP1), which in early developing neurons is not present in 
clusters (Dong et al, 1999). Similarly to p75NTR, the transferin receptor also 
appeared in clusters, but unlike the p75NTR clusters, these were more 
homogenously distributed along the processes (Fig.9C). GRIP-1 exhibited a very 
homogenous pattern and no clustering (Fig.9C). Interestingly, p75NTR clusters 
accumulated preferentially at sites where processes branch (Fig.9D). 
2.2.3) Effects of neurotrophins and acute over-expression of p75NTR
deletion constructs  
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We next tested whether the degeneration of tau::p75NTR neurons caused by the 
prevention of down-regulation of p75NTR, could be affected by treatment with 
neurotrophins. Treatment with either NGF or BDNF at d2, neither accelerated nor 
delayed the degeneration of processes (Fig.10A), suggesting that their 
degeneration is independent of neurotrophin ligand binding. 
To understand which of the domains of p75NTR are necessary for causing 
degeneration, we performed acute transfection experiments with several rat 
p75NTR constructs carrying deletions in different domains. We transfected wild 
type ES cells at day 3 with four constructs: full length p75NTR (p75NTR-FL), p75NTR
lacking the entire extracellular domain (p75NTR?ECD), p75NTR lacking the 
intracellular death domain (p75NTR?DD), and p75NTR lacking the entire 
intracellular domain (p75NTR?ICD). To visualize neurons that have been 
transfected with the p75NTR constructs, we co-transfected with a plasmid 
encoding for GFP. We used an 8 fold lower concentration of the GFP plasmid 
and assumed that GFP-expressing neurons would also have incorporated the 
p75NTR plasmids. We also checked this by staining with the MC192 p75NTR
antibody that recognizes rat p75NTR, but not mouse p75NTR. In all cells analyzed 
(n=12/12), expression of MC192 immunoreactivity co-localized with GFP 
expression (Fig.10C). 
Unexpectedly, transfection with of all p75NTR constructs caused the degeneration 
of processes (Fig.10A). As p75NTR is know to activate signaling by recruiting 
intracellular interactors through its intracellular domain, these results suggest that 
the transfected mutant receptors might interact with endogenously-expressed 
p75NTR in wild type cells. To test this hypothesis, we repeated these experiments 
using p75NTR-/- neurons. While transfection with p75NTR?ECD could still cause 
the degeneration of processes in a p75NTR null background, transfection with 
p75NTR?ICD was no longer able to caused degeneration (Fig.10D). Interestingly, 
deletion of the death domain in p75NTR also cause degeneration (Fig.10D). This 
suggests that the killing activity of p75NTR resides within its juxtamembrane 
intracellular domain and is consistent with a previous study showing that this 
domain, termed “Chopper”, is necessary for inducing cell death in other cellular 
28
systems (Coulson et al, 2000). It should be noted also that in all cases where 
p75NTR was acutely over-expressed, the degeneration of neurons occurred more 
rapidly than in tau::p75NTR neurons, and the processes and cell bodies 
degenerated at the same time. These results further suggest that the acute over-
expression of p75NTR in this system is ligand-independent. 
2.2.4) Involvement of caspase actvivity in p75NTR-mediated neuronal 
degeneration
We next investigated the mechanism by which p75NTR? causes the degeneration 
of processes? First, we asked whether some of the same machinery typically 
involved in programmed cell death played a role, by looking at the distribution of 
caspase activity. We used an antibody that recognizes the active form of 
caspase-3, a central effector caspase in the apoptotic cascade. Strong 
immunoreactivity was observed in tau::p75NTR neurons starting by day 4. It was 
localized to the cell body, but was never present in their processes (Fig.11A). By 
day 5, when all processes have completely degenerated, caspase-3 activity 
remained confined to the cell body, and it co-localized with the nuclei that, at this 
time point, showed signs of pyknosis (Fig.11A). Caspase-3 activity was never 
detected in control neurons (data not shown). To interfere with caspase activity, 
we treated tau::p75NTR neurons starting at day 2 with the inhibitor fmk-Z-VAD, 
which blocks the activity of all caspases by preventing their activation by self-
cleavage. The treatment prevented the death of cell bodies in tau::p75NTR
neurons, as assessed by quantifying cells exhibiting pyknotic nuclear 
morphologies (Fig.11B). However, fmk-Z-VAD did not prevent the degeneration 
of processes (Fig.11C), thus suggesting that the degeneration of processes does 
not require the activity of caspases. 
2.2.5) Involvement of JNK in process degeneration  
We next investigated the role of the c-Jun N-terminal kinase (JNK) in our system. 
JNKs are also referred to as SAPKs, for stress activated protein kinases. These 
enzymes are typically activated by cellular stress (for review see Davies, 2000). 
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JNK can phosphorylate several AP1 transcription factors such as for example c-
Jun, as well as members of the Bcl2 family. Importantly, when acutely over-
expressed in different cell types, p75NTR was shown to induce JNK activity 
(Bhakar et al, 2003). We first examined the distribution of JNK in tau::p75NTR
neurons at day 2 by immunostaining.  While JNK was present both in processes 
and in the cell body, phosphorylated JNK was primarily located in processes 
(Fig.12A). Also in control neurons at day 2, activated JNK was localized to the 
processes exclusively (data not shown). Western blot analysis performed at day 
2 revealed increased levels of phosphorylated JNK in tau::p75NTR lysates 
compared with control lysates (Fig.12B). 
As these observations suggest that JNK may play a role in processes at these 
time points, we used CEP-1347, an inhibitor of JNK signaling that acts by 
blocking the activity of Mixed Lineage Kinases upstream of JNK (Roux et al, 
2002). Treatment of tau::p75NTR neurons at day 2 with CEP-1347 prevented the 
degeneration of processes in a concentration dependent manner (Fig.12C,D). 
Because JNK was previously shown to phosphorylate the pro-apoptotic protein 
BAD (Bhakar et al, 2003), we examined if this also occurred in our system. 
Western blotting revealed no phosphorylated BAD in control nor in tau::p75NTR
lysates at day 2 (Fig.12E). Interestingly, phosphorylated BAD was detected in 
control and tau::p75NTR lysates at day 1 (Fig.12E), indicating that the absence of 
phosphorylated BAD at day 2 was specific. This early phosphorylation of BAD 
might be responsible for the basal level of cell loss detected in control cultures at 
day 1, perhaps as a result of the dissociation procedure that causes abundant 
cell death (data not shown). 
Treatment with CEP-1347 not only prevented the degeneration of processes, but 
it also affected the morphology of neurons. By day 4, CEP-1347-treated 
tau::p75NTR neurons exhibited increased branching, as assessed by the number 
of primary processes originating per cell body (Fig.13A). 
To directly test the role of p75NTR in branching, we also compared control 
neurons to neurons deficient for both p75NTR alleles. In line with the results 
obtained using CEP-1347, p75NTR null neurons exhibited increased branching 
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than control (Fig.13B). Finally, we tested whether ligand binding affects 
branching in wild type cells. Treatment of control neurons with either BDNF or 
NGF resulted in increased branching (Fig.13C). Taken together, these 
experiments indicate that p75NTR plays a role as a negative regulator of process 
branching in ES cell-derived neurons.  
2.2.6) Contribution of mitochondria and the ubiquitin-proteasome system to 
process degeneration 
Given its prominent role in cell metabolism and its involvement in apoptotic cell 
body death, we examined the role of mitochondria in process degeneration in our 
system. To asses the distribution and integrity of mitochondria in neurons, we 
used Mitotracker-Orange, a cell permeable marker that selectively labels healthy 
and active mitochondria. Mitotracker-Orange was applied in vivo for one hour 
and neurons were then fixed and stained. Active mitochondria were present in 
the cell body and along processes of control and tau::p75NTR neurons at day 2 
(Fig.14A). To further confirm that mitochondria were active, we double stained 
with antibodies against cytochrome C (Fig.14B), which localizes exclusively to 
healthy mitochondria and is released upon mitochondria outer membrane 
polarization during programmed cell death. This revealed that the majority of 
Mitotracker-Orange-labeled mitochondria (~80%) co-localized with cytochrome C 
(Fig.14B). In processes, mitochondria clusters exhibited an elongate shape of 
about ~0.5-3 ?m in length (Fig.14A). Clusters were evenly distributed along the 
process all the way to the growth cones, and were separated by 2±2 ?m. By day 
4, active mitochondria were still detected but they adopted a different morphology 
that was more compact (Fig.14A). 
It has been shown that a compact mitochondrial morphology correlates with 
increased intracellular calcium levels (Murphy et al, 1996). Mitochondria can take 
up large quantities of calcium and this leads to their compact morphology and to 
increase production of ATP and of reactive oxygen species (ROS, Brookes et al, 
2004). Thus, we asked whether calcium plays a role in process degeneration. 
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Treatment of tau::p75NTR neurons with EGTA, an extracellular calcium chelator, 
could partially delay the degeneration of processes (Fig.14C). 
We next tested whether increased mitochondrial activity would affect process 
degeneration. Treatment with creatine or sodium pyruvate, which are known to 
promote mitochondrial activity and to increase ATP levels respectively (Li et al, 
2004), accelerated the degeneration of processes in tau::p75NTR neurons 
(Fig.14C). Together, these results suggest that the levels of mitochondria-derived 
ATP contribute to the degeneration of processes.
As interference with the ubiquitin proteasome system (UPS) has been recently 
shown to prevent the degeneration of axons in vitro (Zhai et al, 2003) and in vivo 
(Watts et al, 2003), we asked next if this was also the case in our system. 
Treatment of tau::p75NTR neurons with MG-132 could modestly prevent process 
degeneration at day 4 (Fig.14D). While this effect was observed with low 
concentrations of MG-132 (0.2 mM), higher concentrations of MG-132 (2 mM), 
which were shown to protect axotomized axons (Zhai et al, 2003), were toxic for 
our neurons (data not shown). It is conceivable that since our experiments were 
performed with early developing neurons, the UPS may be important for the 
survival of these cells. Indeed, pharmacological inhibition of the UPS has been 
shown to compromise the survival of cultured sympathetic neurons 
(Klimaschewski et al, 2003) and of motoneurons in spinal cord slice cultures 
(Tsuji et al, 2005).
2.2.7) Involvement of RhoA signaling in process degeneration 
As essentially all cells behave similarly in our system, we next set out to identify 
early biochemical changes causing the degeneration of processes by proteomic 
analyses using 2-dimensional gel electrophoresis, a method that allows cell 
populations to be compared on the basis of their protein expression profiles. It is 
based on the separate labeling of lysates with different fluorescent markers, 
which allows proteins from each lysate to be resolved in the gels. Control and 
tau::p75NTR cells were lysed at day 2, before any signs of process degeneration. 
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In 2 independent experiments, we identified 12 proteins that were reproducibly 
de-regulated in tau::p75NTR neurons (Fig.15). Since several proteins were found 
in multiple spots on the gel, this suggests that some of the observed changes 
might be due to post-translational modifications, rather than to changes in the 
total levels of expression. The proteins identified included gelsolin, cofilin, destrin, 
calponin-3, tropomyosin, and caldesmon (Fig.15). All of these proteins have been 
directly linked with the regulation of actin filaments. The differential expression of 
all these proteins is consistent with previous observations indicating that p75NTR
is a major regulator of Rho activity, a small GTPase targeting the actin 
cytoskeleton (Jaffe and Hall, 2005). Thus, we asked whether in our system 
p75NTR also controls the Rho pathway. We measured the levels of RhoA activity 
in day 2 neurons by pulling down GTP-bound RhoA (the active form of RhoA) 
using beads coupled with the Rho binding domain of the protein Rhottekin (Reid 
et al, 1996). This experiment indicated that Rho-GTP levels were higher in 
tau::p75NTR compared with control cells (Fig.16A). The levels of total RhoA 
protein were not significantly changed between tau::p75NTR and control neurons, 
as measured by Western blotting (Fig.16A).
Also at day 2, staining for F-actin revealed defects in the actin cytoskeleton in 
tau::p75NTR cells compared with control neurons. The filaments became 
abnormally beaded throughout the processes as well as in the cell body 
(Fig.16B). This was likely due to rearrangements in the distribution of the 
filaments, and/or changes in the polymerization state of actin, as the total levels 
of actin measured by Western blot for ??actin were not changed (Fig.16C). At 
this time point, the microtubules of tau::p75NTR neurons were neither beaded nor 
fragmented, and were indistinguishable from those in control cells (Fig.16B). 
These observations suggest that in our system, the actin cytoskeleton becomes 
affected before the microtubules. To test whether the increased Rho activity and 
the defects on F-actin have a causal role in the degeneration of processes, we 
interfered with the Rho pathway. Treatment with Y27632 or HA1077 at day 2, two 
inhibitors of the RhoA downstream effector Rho kinase, rescued process 
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degeneration in tau::p75NTR neurons (Fig.16D). This rescue was less dramatic 
than the JNK signaling inhibitor (compare with Fig.12D). 
As the activation of RhoA by p75NTR has previously been shown to be linked with 
inhibition of process elongation, we also examined if the inhibitors of Rho Kinase 
would also have an effect on the branching of tau::p75NTR neurons. The results 
shown in Figure 13A revealed that treatment with Y27632 promotes process 
branching in tau::p75NTR neurons. This effect was less pronounced than the 
effect of CEP-1347 in process branching. One explanation for this is that CEP-
1347 is a more efficient inhibitor of JNK signaling, than Y27632 is for the RhoA 
pathway. Alternatively, the JNK pathway may play a more significant role in 
process branching in tau::p75NTR neurons. 
2.2.8) Identification of Galectin-1 in tau::p75NTR neurons 
The analysis of proteins differentially expressed using proteomics also revealed a 
threefold up-regulation of a protein in tau::p75NTR lysates that was identified by 
mass spectrometry as Galectin-1 (Fig.15). Galectin-1 is a member of the a family 
of lectins called the Galectins (for review see Liu and Rabinovich, 2005). Lectins 
are proteins that bind specific carbohydrates attached to other proteins or lipids. 
The Galectin family is highly conserved from C. elegans to human, consisting of 
about 15 family members that share a carbohydrate-recognition domain (CRD) 
with specificity for ?-galactose. In order to confirm the up-regulation of Galectin-1 
in tau::p75NTR neurons, we performed Western blots on day 2 neurons. Galectin-
1 was expressed at higher levels by tau::p75NTR neurons as compared with 
control cells (Fig.17A). This up-regulation could be prevented by treatment of 
tau::p75NTR neurons at day 1 with the JNK signaling inhibitor CEP-1347 and with 
the Rho kinase inhibitor Y27632 (Fig.17B). Reverse transcription-PCR also 
revealed a marked up-regulation of Galectin-1 mRNA levels by tau::p75NTR
neurons at day 2 (Fig.17B), which was also prevented by CEP-1347 and Y27632 
(Fig.17B).
Since a recent study showed that another family member, Galectin-3, facilitates 
the apical transport of p75NTR in polarized cells (see Discussion), we tested the 
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possibility that Galectin-1 could also directly interact with p75NTR.
Immunoprecipitation with p75NTR antibodies pulled down endogenous Galectin-1, 
and substantially more Galectin-1 was precipitated from tau::p75NTR lysates than 
from control lysates (Fig.17C). 
2.2.9) Involvement of Galectin-1 in process degeneration
We then examined whether Galectin-1 participates in the degeneration of 
processes. Because increased Galectin-1 levels were detected in tau::p75NTR
neurons, and since this lectin likely interacts with the glycosylated domain of 
p75NTR that is situated in the ECD, we hypothesized that Galectin-1 may act 
extracellulary. In order to displace Galectin-1 from its binding sites, we used a 
recombinant protein consisting of the entire glycosylated ECD of p75NTR linked to 
a human Fc region. Treatment of tau::p75NTR neurons at day 2 with soluble 
p75NTR protein prevented the degeneration of processes in a concentration 
dependent manner (Fig.18A,B). 
We next asked whether Gallectin-1 may be an effector of neuronal degeneration. 
Control neurons were treated at day 3 with exogenously applied recombinant 
Galectin-1. This led to the degeneration of processes, which became evident 
already after 24 hours of treatment (Fig.18C-E), and was later followed by the 
death of the cell bodies. The morphology of degenerating processes was similar 
to that observed in tau::p75NTR neurons (Fig.18D). Treatment of control neurons 
with Galectin-1 at day 9 also killed processes in a manner similar to day 3 
neurons (data not shown). The killing effects of recombinant Galectin-1 could be 
prevented by co-treatment with soluble p75NTR (Fig.18C,E). To test if Galectin-1’s 
killing effect depends on its ability to bind to carbohydrates, we also co-treated 
control cells with Galectin-1 and lactose, a disaccharide consisting of sucrose 
and galactose. Like soluble p75NTR, lactose also prevented the killing effect of 
Galectin-1 (Fig.18C,E). This suggests that Galectin-1 may cause degeneration 
by binding to sugar residues present on cell surface molecules. 
The sugar binding activity of Galectin-1 is known to depend on its state of 
oxidation. Indeeed, it seems to come out of the cells with cystein residues not 
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involved in the formation of disulfide bridges (Barondes et al, 1994). In our 
experiments we always used Galectin-1 that was prepared in the presence of 
DTT to avoid oxidation. We therefore compared the effects of Galectin-1 
prepared with DTT (reduced) with that of Galectin-1 prepared without DTT 
(oxidized). This revealed that at the concentrations at which reduced Galectin-1 
causes neuronal degeneration, oxidized Galectin-1 does not (FIG.18F). 
Since the Galectins are a large family of proteins, we also compared the effects 
of Galectin-1 to that of Galectin-3 on control neurons, as these lectins have 
recently been shown to have similar effects on activated T cells (Stilmann et al, 
2006). Interestingly, unlike Galectin-1, Galectin-3 failed to cause neuronal 
degeneration in control cells (Fig.18F), thus indicating that sugar binding alone 
may not be sufficient to trigger process degeneration.   
2.2.10) The killing effect of recombinant Galectin-1 does not require p75NTR
We next investigated the possibility that Galectin-1 would mediate its killing 
activity by binding to p75NTR. Indeed, p75NTR is highly glycosylated in its ECD and 
interacts with Galectin-1 (see Fig.17C) as well as with another unrelated lectin, 
wheat germ agglutinin (WGA). WGA is a protein of 36,000 molecular weight 
isolated from Triticum vulgaris (Costrini & Kogan, 1981; Vale & Shooter, 1982;
Buxser et al., 1983; Grob & Bothwell, 1983). Like with Galectin-1, we found that 
treatment of control neurons at day 2 with exogenous WGA caused the 
degeneration of processes (Fig.19). By contrast, neuronal processes of neurons 
with a full deletion of both p75NTR alleles escaped the killing effects of WGA 
(Fig.19). Treatment with Galectin-1 caused the death of both control as well as 
p75NTR-/- neurons (Fig.19). These results show that while WGA acts primarily 
through p75NTR, exogenous Galectin-1 does not require p75NTR expression to kill. 
In line with the view that exogenous Galectin-1 activates pathways additional to 
those triggered by p75NTR, co-treatment of control neurons at day 2 with Galectin-
1 and either the Rho kinase or the JNK signaling inhibitors, did not prevent the 
degeneration of processes (data not shown). 
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2.2.11) Recombinant Galectin-1 kills neurons isolated from the developing 
cerebral cortex 
We tested if Galectin-1 could also cause the degeneration of primary neurons. As 
the ES cell-derived neurons used in our system resemble cultures of neurons 
isolated from the developing cerebral cortex (Bibel et al, 2004), we next used 
neurons isolated from embryonic day 16.5 mouse cortex and treated them with 
recombinant Galectin-1 at day 5 after plating. Like with ES cell-derived neurons, 
Galectin-1 caused the degeneration of their processes followed by the cell body 
(Fig.20). The first signs of process degeneration were observed after 36 hours of 
Galectin-1 treatment, compared with 24 hours in ES cell-derived neurons. When 
the first signs of degeneration were detected in processes, the time elapsed 
between this point and the death of the cell bodies was similar to that observed in 
ES cell-derived neurons, being roughly 24 hours. The killing effect of Galectin-1 
could also be prevented by co-treatment with either lactose or the soluble p75NTR
fusion protein (Fig.20). 
2.2.12) Excitotoxicity increases Galectin-1 levels in vivo and is prevented 
by extracellular decoys  
To test whether Galectin-1 plays a role during neuronal degeneration in vivo, we 
focused on a well-established model of neuronal degeneration caused by 
excitotoxicity. The medial septum is a region of the basal forebrain that contains 
large numbers of cholinergic neurons. These cells have projections towards 
different brain structures, including hippocampus, cortex and amygdala, and are 
involved in the regulation of cognitive function (Everritt and Robbins, 1997). 
Unlike most CNS neurons, basal forebrain cholinergic neurons continue 
expressing p75NTR at high levels even in the adult (Dechant and Barde, 2002). A 
previous study has shown that the delivery of exposure of the medial septum to 
excitotoxins leads to the loss of cholinergic neurons (Oh et al, 2000). In addition, 
this led to increased levels of p75NTR expression and the degeneration of the 
septal neurons could be prevented by antibodies against p75NTR as well as by 
inhibitors of protein synthesis (Oh et al, 2000). 
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We injected the N-methyl-D-aspartate (NMDA) glutamate receptor agonist 
ibotenic acid (IBO) stereotaxically onto the medial septum of adult rats, and 
assessed its effects 24 hours later (Fig.21A). Immunostaining revealed a local 
increase in Galectin-1 reactivity (Fig.21B). 
We next quantified the number of cholinergic neurons by staining for p75NTR,
which labels both their processes and cell bodies. IBO injection resulted in a 
significant loss of p75NTR-positive neurons as compared with sham (Fig.22A,C). 
High magnification images revealed that similarly to our in vitro system, the 
processes of cholinergic neurons degenerated before the cell bodies (Fig.22B); 
the majority of cholinergic neurons in IBO-injected animals were devoid of 
processes, their cell bodies appeared more compact and exhibited nuclear 
pyknosis, while sham neurons had several processes and healthy cell bodies. 
The staining intensity for p75NTR was stronger in degenerating neurons than in 
sham, suggesting an up-regulation in protein levels (Fig.22B). Co-injection of the 
soluble p75NTR fusion protein, lactose or an anti-Galectin-1 antibody prevented 
both the loss of cholinergic neurons and of their processes (Fig.22A,C,D). Given 
our in vitro results showing that CEP-1347 prevents Galectin-1 expression and 
the degeneration of tau::p75NTR neurons, we tested its effects in our in vivo 
system. Co-injection of CEP-1347 and IBO resulted in decreased staining 
intensity for Galectin-1 (Fig.21B) and it also prevented cholinergic neuron 
degeneration (Fig.22A,C,D). These results thus indicate that endogenous 
Galectin-1 is up-regulated after excitotoxicity and is involved in the degeneration 
of neurons. 
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3. DISCUSSION
3.1) DEVELOPMENTAL POTENTIAL OF PROGENITOR 
CELLS
3.1.1) RA-treated ES cells generate uniform and defined progenitors 
A key aspect of the work presened in this Thesis was the availability of a 
recently-developed system allowing the generation of uniform cell populations 
(Bibel et al, 2004). Unlike previous protocols leading to rather heterogenous and 
poorly defined cells, virtually all the progenitors we used have the identity of RG 
cells. Prior to implantation, all cells in the RA-treated aggregates expressed 
Nestin, Sox2, Pax6, RC2, and GLAST. Only very few cells (less than 1%) 
expressed the interneuron marker Lim1/2 and the motoneuron markers Hb9 and 
Isl1. No cells were found to be GFP-positive in intact aggregates or during the 
first hours following their dissociation (data not shown). These results indicate 
that RA-treated ES cell aggregates contained a homogeneous cell population 
with a profile of marker expression corresponding to in vivo existing RG cells. By 
contrast, previous studies using similar markers indicated cellular heterogeneity 
of RA-treated aggregates. For example, other differentiation protocols led to a 
mix of cells expressing Pax6, Pax7 and Nkx2.2 (Renoncourt et al., 1998; 
Wichterle et al., 2002). In the neural tube, expression of these markers is 
segregated; dorsal progenitors express Pax7, mid-dorsal to mid-ventral 
progenitors express Pax6 and ventral progenitors express Nkx2.2 (Ericson et al, 
1997). These different populations generate distinct neuronal types. In our study, 
virtually all the cells expressed Pax6 prior to transplantation, while none 
expressed Pax7 or Nkx2.2.
The homogeneity of our RA-treated ES cells is likely to explain differences with 
other studies in the progeny obtained. For example, Wichterle et al (2002) failed 
to detect donor-derived motoneurons if their RA-treated ES cells were treated 
only with RA and without sonic hedgehog (Wichterle et al, 2002). By contrast, we 
observed significant numbers of motoneurons derived from our aggregates 
treated only with RA. As motoneurons constitute a fraction of the mouse-derived 
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cells, it can be expected that if the progenitor population is heterogeneous at the 
time of implantation, it likely contains fewer cells able to enter the motoneuron 
differentiation pathway. Presumably in our case, sonic hedgehog or other 
signalling molecules delivered by the host drive the generation of motoneurons at 
the appropriate location following implantation of sufficient numbers of competent 
cells.
Does the differentiation of ES cells with RA resemble an in vivo-existing 
mechanism? Retinoic acid plays important regulatory roles at different stages of 
embryonic development (Morriss-Kay and Sokolova, 1996). During gastrulation, 
after neural tissue has been induced by noggin- and follistatin-antagonism of 
BMPs, RA up-regulates the expression of pro-neural genes (for review see 
Maden, 2002). RA is later required for anterior neural progenitors to acquire a 
more posterior identity, and to subsequently differentiate into distinct neuronal 
subtypes of the hindbrain and spinal cord (Muhr et al, 1999; Pierani et al, 1999). 
The mechanisms by which RA exerts its effects on neural differentiation of ES 
cells remain unclear and may not be physiological, though we note that in ES 
cells RA induces the expression of a Wnt antagonist called Sfrp2 (Aubert et al, 
2002). Interestingly, the addition of recombinant Sfrp2 mimmics the effects of RA 
(Aubert et al, 2002). Thus RA acts, at least in part, by interfering with one of the 
factors known to maintain ES cells undifferentiated (see Introduction). 
3.1.2) Large numbers of ES cells differentiate into neurons in the host  
Six days after implantation, ES cell-derived progenitors survived in very large 
numbers in the chick host and the vast majority of them differentiated into 
neurons. Donor cells differentiated into Lim1/2+ interneurons and into 
motoneurons that were Hb9+ and Isl1+. Motoneurons extended axons towards 
the periphery and expressed the neurotrophin receptors p75NTR and Trk in their 
cell bodies and axons. In addition to the identification of donor cells using GFP, 
we also monitored by nuclear staining the fate of other cells that survived but 
failed to differentiate into neurons. Both in the spinal cord and in the DRG, about 
80% of the mouse nuclei localized to GFP+ cells. Previous studies indicated that 
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there is a complete overlap between cells expressing GFP from the tau locus and 
those positive for the antibody TuJ1 that recognizes a neuron-specific form of 
tubulin (Tucker et al., 2001). In addition, we also found that in the spinal cord, 
many GFP-negative donor cells expressed either Lim1/2 or Hb9 (data not 
shown). As progenitor cells differentiating into neurons start expressing these 
markers prior to exiting the cell cycle, it is likely that these Lim1/2+/GFP- and 
Hb9+/GFP- cells were on their way to become post-mitotic interneurons or 
motoneurons, respectively. While it may seem surprising that we only detected 
few cells not belonging to the neuronal lineage in the progeny of our precursor 
cells, it should be kept in mind that our experiments did not go beyond E8, which 
is before the time when large number of astrocytes are generated in the spinal 
cord. It is possible that some of the GFP-negative cells may later go on to 
differentiate into astrocytes. These results show that our progenitor cells 
generate mostly neurons after implantation, which is in line with recent evidence 
suggesting that Pax6-positive RG cells are neuronal progenitors (see 
Introduction). In addition, our results indicate that donor cells are able to respond 
to patterning signals in the spinal cord, generating spinal cord interneurons and 
motoneurons in a time- and in a position-dependent manner. At present, in vivo 
cell lineage studies have not yet rigorously proven that Pax6-positive RG cells in 
the spinal cord generate motoneurons and subtypes of interneurons, but this 
appears quite likely. The pattern of expression of RG markers and of Pax6 in the 
spinal cord, as well as the decrease of motoneuron numbers in the small eye
mutant (Ericson et al., 1997) are compatible with this interpretation. 
3.1.3) RA-treated ES cells fail to elongate axons in the DRG 
Donor cells also exhibited a migratory behaviour and colonized the DRG, 
perhaps because they follow the stream of migratory neural crest cells. Strikingly, 
while most donor cells also differentiated into GFP+ neurons in the host DRG, 
they failed to elongate axons and to express Brn3a and Isl1, which are 
expressed by most neurons in that structure. These results can not be accounted 
by an intrinsic restriction of RA-treated cells to extend axons and to express 
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these markers, since the same cells were capable of doing so when located in 
the spinal cord.  Moreover, while donor motoneurons expressed both p75NTR and 
Trk receptors, donor neurons in the DRG did not express detectable levels of Trk 
receptors. By contrast, these neurons expressed p75NTR at relatively high levels. 
Typically, signaling via Trk receptors supports neuronal survival and axonal 
elongation (Huang and Reichardt, 2003). By contrast, signalling via p75NTR leads 
to opposite effects (Dechant and Barde, 2002). It is thus possible that p75NTR
expression by donor neurons in the DRG in the absence of detectable 
expression of Trk receptors, may account for their failure to elongate axons. 
During development, sensory neurons expressing p75NTR also express at least 
one type of Trk receptors (Wright and Snider, 1995). Our results suggest then 
that neurons located in the DRG do not extend axons by default even in the 
highly conducive environment provided by developing DRG. While we do not 
know why Trk receptors are not expressed when the ES cell-derived progenitors 
are located in the DRG, we note that they also failed to express the POU 
transcription factor Brn3a. It has been shown that the expression of all Trk 
receptors is compromised in the trigeminal ganglia of Brn3a-/- mice, while the 
expression of p75NTR is not affected (Huang et al., 1999). In addition, Brn3a has 
recently been shown to directly induce transcription of TrkA in the DRG (Ma et 
al., 2003). Thus, the absence of Brn3a expression by donor neurons in the DRG 
may be related with their failure to express Trk receptors. Why the expression of 
Brn3a is not turned on is unclear, but we note that in the DRG, the progenitors of 
Brn3a cells are not Pax6-positive, suggesting that Pax6 or other factors may 
repress the acquisition of alternative phenotypes. 
In view of these results with the DRG, we performed similar implantation 
experiments with RA-untreated ES cells. Virtually all ES cells at the time of 
implantation expressed Oct3/4, one of the markers correlating with pluripotency 
of ES cells (Niwa et al., 2000; Boiani et al., 2002). We found that these cells also 
survived in large numbers after implantation. Like RA-treated cells, they also 
differentiated into Lim1/2+ interneurons, and into Hb9+ and Isl1+ motoneurons 
extending long axons towards the periphery that were positive both for Trk and 
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p75NTR neurotrophin receptors. We observed however that RA-untreated ES cells 
generated fewer motoneurons than RA-treated cells, as judged by the expression 
of Hb9 and Isl1. Recent studies indicated that somite-derived RA plays an early 
role in the acquisition of a neural fate by cells in the neural tube (Diez del Corral 
et al., 2003), and that the same molecule can further promote these cells into a 
motoneuron differentiation pathway, even in the absence of sonic hedgehog 
(Novitch et al., 2003). It is therefore conceivable that pre-treatment with RA may 
not only induce neural differentiation of ES cells, but also bring these cells closer 
to a motoneuron fate. 
ES cells also colonized the host DRG, but in contrast to RA-treated cells, they 
expressed the markers Brn3a and Isl1. These cells also elongated axons outside 
the DRG both towards the spinal cord and the periphery, and they expressed Trk 
receptors in addition to p75NTR. The proportion of ES cells colonizing DRG and 
differentiating into neurons in that structure was similar to that observed for RA-
treated cells. Thus, the failure of RA-treated cells to express DRG markers and to 
elongate axons does not result from a higher number of cells colonizing the DRG 
and differentiating into neurons. We also note that this system of ES cell 
implantation into the chick embryo seems to work reliably in so far as neither RA-
treated nor RA-untreated cells colonizing the DRG ever expressed spinal cord 
markers.
3.1.4) Testing the differentiation potential of progenitor cells using in vivo 
approaches
The differentiation potential of multipotent cells has been explored extensively in 
culture conditions using exogenous extracellular signals. However, the factors 
added might not be sufficient to explore the entire differentiation potential of 
these cells. A good test of the developmental potential of progenitor cells is to 
confront these cells with an in vivo system. The avian embryonic nervous system 
is ideally suitable for this as defined times and locations can be chosen to 
transplant cells when for example, active neurogenesis, cell migration, or 
gliogenesis are occurring (for review see Temple, 2001).
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Previous studies have reported on the use of ES cell-derived progenitors for cell 
transplantation. In particular, Brustle and colleagues transplanted in vitro-
differentiated neural progenitors from mouse ES cells into the brain ventricles of 
rats (Brustle et al, 1997). These cells populated the brain parenchyma where 
they differentiated into astrocytes and neurons. Similar results were also reported 
using human ES cell-derived neural progenitors implanted into the brains of mice 
or rats (Reubinoff et al, 2001; Zhang et al, 2001), and with mouse ES cell-derived 
neural progenitors implanted into the damaged spinal cord of rats (McDonald et 
al, 1999). While these studies showed that ES cell-derived neural progenitors 
responded to host signals, the extent to which they survived and differentiated in 
the host remains unclear and appeared to be limited. Furthermore, the in vitro-
differentiated neural progenitors were not shown to correspond to a defined 
population of neural progenitors beyond Nestin positivity. Kim et al and Wichterle 
et al showed that mouse ES cells could differentiate in vitro into dopaminergic 
neurons and motoneurons respectively (Kim et al., 2002; Wichterle et al., 2002). 
These cells were even able to integrate as dopaminergic neurons in the striatum 
of hemiparkinsonian rats, and as motoneurons in the chick embryo spinal cord 
respectively. However, the frequency of these integration events was not 
reported in these studies. In our experiments, cells survived in large numbers, 
contributed to form a spinal cord of normal size and morphology and 
differentiated into spinal cord neurons. Therefore, our experimental approach 
offers now the possibility to examine the function of genes involved in neural cell 
fate specification and axonal elongation using genetically modified ES cells. An 
interesting prospect would be for example, to test the behaviour of neurons 
derived from ES cells engineered not to respond to myelin associated molecules, 
and ES cells deficient for the Nogo receptor, p75NTR and LINGO, could prove 
useful to test this suggestion. By implanting cells deficient for these receptor 
components, one could assess axonal elongation in an otherwise wild type 
environment. This would be of particular interest since several of these 
molecules serve many other roles in development, and thus the analysis of full 
knockout animals is often complex. 
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3.1.5) Restricted developmental potential of RA-treated ES cells
In the developing brain, neurons are generated from different types of 
progenitors. During early stages, only neuroepithelial cells are present, but as 
development progresses these cells differentiate into at least two distinct types of 
progenitor cells. The first type to appear is the basal progenitors, and is followed 
by RG cells (Kriegstein and Gotz, 2003). These different progenitor populations 
can be identified by their different morphology, location, and profile of marker 
expression. RG cells are distributed throughout the dorsal-ventral axis, but those 
located dorsally seem to differ functionally from those located ventrally.  It has 
been proposed that only dorsally located RG cells are neurogenic (Malatesta et 
al, 2003), and cell fate mapping experiments indicated that these cells generate 
the majority of excitatory neurons in the cerebral cortex and in the hippocampus 
(Malatesta et al, 2003). By contrast, ventral RG cells do not substantially 
contribute to the neuronal population found in the striatum or to the interneuron 
population in the cerebral cortex, and these neurons seem to be the progeny of 
the basal progenitors (Gotz and Barde, 2005). Recently, this conclusion was 
challenged by Anthony et al. (2004) who suggested that RG cells are neuronal 
progenitors throughout the entire brain. In their study, the authors mapped the 
progeny of RG cells by crossing a line that expresses Cre recombinase from the 
BLBP promoter to reporter lines (Anthony et al, 2004). The caveat of this study 
however is that while BLBP expression in RG cells becomes detectable by E12, 
its mRNA is already present in neuroepithelial cells by E10, a time when RG cells 
are not yet present. In line with the view that the BLBP construct used by 
Anthony et al (2004) may have driven a premature expression of Cre, similar 
results to those obtained using the BLBP-Cre line were obtained using a Nestin-
Cre line (Backman et al, 2005). 
What are the molecular differences between dorsally- and ventrally located RG 
cells that could account for their different neurogenic potential? It appears that 
one key determinant of the neurogenic potential of dorsally-located RG cells is 
the expression of the transcription factor Pax6 (Heins et al., 2002; Malatesta et 
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al., 2003). During development, Pax6 expression is restricted to the dorsal 
telencephalon, where neurogenic RG cells are located, while it is absent from the 
ventral telencephalon (Heins et al, 2002). Moreover, fewer neurons are found in 
the cortex of Pax6 mutant mice (Heins et al, 2002). Perhaps the most striking 
piece of evidence suggesting that Pax6 plays a major role as a neurogenic factor 
is that when over-expressed, Pax6 can instruct non-neurogenic mature 
astrocytes into neurogenesis (Heins et al, 2002). In addition, a recent study 
showed that Pax6 is essential for adult neurogenesis in the olfactory bulb (Hack 
et al, 2005). 
The RA-treated ES cells used in our study have the antigenic profile of those 
found in the developing dorsal, but not ventral telencephalon. While previous 
work with these cells showed that in vitro they differentiate into neurons with the 
characteristics of pyramidal cells (Bibel et al., 2004), we now find that they can 
also respond to extracellular signals and differentiate according to their position 
in the embryo. However, their differentiation potential is restricted and they seem 
to generate only the neural progeny that is expected from their developmental 
history and location. In particular, they cannot acquire the antigenic and 
morphological features of peripheral sensory neurons. Our results then raise the 
question of the nature of the molecular determinants that restrict the 
differentiation potential of RG cells. One possibility is that Pax6 not only acts to 
commit RG cells to differentiate into specific neuronal subtypes, but that it also 
actively represses the differentiation into other different subtypes. In line with this 
notion, unpublished work from our laboratory suggests that in the absence of 
functional Pax6, RG cells are still generated, but their neuronal progeny differs 
from that obtained from RG cells wild type for Pax6 (N. Nikoletopoulou and Y.-A. 
Barde, personal communication).
3.1.6) What are developmental restrictions good for? 
Examples of developmental restrictions in the vertebrate nervous system were 
most extensively documented in the neural crest. These cells have an extensive 
differentiation potential, as there are few tissues of the vertebrate body to which 
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they do not contribute. The introduction of the quail-chick chimera system by Le 
Douarin and colleagues several years ago pioneered the use of avian 
transplantation experiments to probe the developmental potential of neural crest 
cells (see review by LeDouarin et al, 2004). This consisted on the isolation of 
neural crest cells from any region along the anterior-posterior axis of the quail 
embryo and the transplantation into chick donors. Moreover, these experiments 
allowed for crest cells to be transplanted at different locations and at different 
developmental time points. An important conclusion from these studies was that 
the differentiation of neural crest cells into different cell types depends on the 
environment they are confronted with (see for example Bronner-Fraser and 
Fraser, 1989). In addition, they indicated that neural crest cells are not restricted 
into generating specific cell types prior to their migration from the neural tube. 
However, studies that most critically assessed the potential of neural crest cells 
indicated that these cells become restricted as they migrate towards their targets 
(Sieber-Blum 1989; Bronner-Fraser and Fraser, 1988; Bronner-Fraser and 
Fraser, 1989; Raible and Eisen, 1994). Therefore, it appears that developmental 
restrictions are a commonality among progenitor cells throughout the nervous 
system. Because of the remarkably large number of different cell types in an 
organism, the purpose of restricting cell potential in terms of development, 
evolution and disease, may not be particularly obvious at first glance. A simple 
explanation however, is that evolution has found a way to prevent the production 
of inappropriate cell types, at the wrong place and time, by restricting the 
phenotypes that any given progenitor can generate.
Interestingly, while neural crest cells are a transient population in the embryo, it 
was suggested that some of them persist in adult tissues. Studies showed that 
cells with the characteristics of neural crest cells can also be isolated from adult 
peripheral tissues and that, if transplanted back into younger embryos, they are 
able to migrate and generate some of the cell types normally produced by neural 
crest cells (Stemple and Anderson, 1992; Morrison et al, 1999). Thus, some 
neural crest cells may not completely disappear after development is completed, 
but instead remain as neural stem cells in the PNS. This may also be the case 
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for RG cells in the CNS, as it was shown that while most of them differentiate into 
neurons and astrocytes during development, some of them become neural stem 
cells in the adult SVZ and dentate gyrus (Garcia et al, 2004).
3.2) NEURONAL DEGENERATION 
Given our results showing that lack of axonal elongation in the DRG correlated 
with expression of p75NTR, we examined the role of this receptor during neuronal 
differentiation of ES cell-derived neurons. As discussed below, we found that 
preventing the downregulation of p75NTR in these cells causes the degeneration 
of neuronal processes and the death of cell bodies, and that these result can be 
explained at least in part, by an up-regulation of the endogenous lectin Galectin-
1.
3.2.1) Synchronous neuronal degeneration caused by the controlled 
expression of p75NTR
In our system, all neuronal processes degenerate at day 4, and they are followed 
24 hours later by the death of the cell bodies. Synchronicity of differentiation is a 
key aspect of our procedure, and experiments using a GFP cDNA introduced in 
the tau locus confirmed phase contrast observations indicating that the 
degeneration of processes is synchronous in our system. We also extensively 
tested whether the presence or absence of tau would alter process degeneration 
and never found any difference between wild type and mutant ES cells with one 
or both tau alleles eliminated (data not shown). The comparison of BrdU 
incorporation between day 2 and day 3 was a further confirmation of 
synchronicity.
3.2.2) Role of JNK in process degeneration
Immunostaining experiments with tau::p75NTR neurons revealed increased JNK 
activity along their processes, but not in the cell body. Also, inhibition of the JNK 
pathway with CEP-1347 prevented process degeneration. CEP-1347 was initially 
developed as an analogue of the naturally-occurring, bacterially-expressed bis-
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ethyl-thiomethyl small molecule, K252a. Unlike CEP-1347, K252a is a rather 
unspecific kinase inhibitor that interferes with the activity of serine/threonine 
kinases, phosphatidyl inositol 3-Kinase, protein kinase C, and the tyrosine kinase 
of all three Trk receptors (for review see Wang et al, 2004). By contrast, CEP-
1347 does not interfere with Trk receptor kinase activity, but efficiently prevents 
the activation of JNK by blocking its upstream Mixed Lineage Kinase (Roux et al, 
2002). Importantly, CEP-1347 has been shown to have a very efficient role in 
preventing the degeneration of neurons in different in vitro and in vivo paradigms. 
These include cultured sympathetic neurons deprived of NGF (Harris et al, 
2002b), cerebellar granule neurons grown in low potassium levels (Harris et al, 
2002a), dissociated spinal motoneurons grown at low density (Maroney et al, 
1998), cortical neurons treated with recombinant A? (Bozyczko-Coyne et al, 
2001), hair cells in an auditory-based in vivo degeneration paradigm (Pirvola et 
al, 2000), and dopaminergic neurons in an animal model of Parkinson’s disease 
(Saporito et al, 2000). CEP-1347 also prevents the degeneration of cholinergic 
neurons of the rodent basal forebrain that were injured either by axotomy (Haas 
et al, 1998) as well as by exposure to IBO (Hass et al, 1998; Saporito et al, 
1998), in a similar manner to our experiments here. Importantly, the protective 
effect of CEP-1347 in most of these systems, including ours, covered both the 
cell bodies as well as the processes of neurons. This is unlike the action of 
caspase-3 inhibition that only prevents the death of neuronal cell bodies. 
While JNK and caspase activities are localized to different cellular compartments, 
we find that p75NTR is expressed at the surface of both processes and cell 
bodies. Cell body death could be triggered by a signal generated within 
processes and then transported towards the cell body. Inhibition of JNK signaling 
may prevent the generation of such signal. In addition, JNK activity might 
contribute both to programmed cell death and to process degeneration, but the 
levels of JNK activity in the cell body might be lower and hence more difficult to 
detect than in processes. Nevertheless, it seems that p75NTR-induced neuronal 
degeneration proceeds in a way such that processes are more vulnerable than 
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the cell body, perhaps simply because the nucleus, ER and Golgi apparatus are 
contained within the cell body. 
Our results also open the question of which JNK isoforms are activated and what 
their targets are in processes. Three different genes encode for JNK1, JNK2 and 
JNK3, and all of these can undergo differential mRNA processing, resulting in 
more than ten different JNK proteins (Davies, 2000). We do not know which JNK 
isofroms are controlled by p75NTR in our system since the JNK antibodies we 
used would recognize all JNK species. We note however that JNK1 is the 
predominant activated form in cultured cortical neurons (Coffey et al, 2000; 
Bjorkblom et al, 2005). 
While we do not know the targets of JNK in neuronal processes, we did not find 
evidence of mitochondrial damage until very late stages of process degeneration, 
as assessed by staining for Mitotracker-Orange and for cytochrome C, or by 
western blot for phosphorylated Bad. This is unlike what was found by others 
using cell bodies (Bhakar et al, 2003). JNK may target components of the 
cytoskeleton, and a number of studies suggested that JNK1 controls microtubule 
dynamics in processes by regulating the phosphorylation state of microtubule 
associated proteins (Chang et al, 2003). We note that JNK1-/- mice have been 
reported to exhibit defects in the anterior commissure tract and a progressive 
loss of microtubules in axons and dendrites (Chang et al, 2003). JNK1 interacts 
with, and phosphorylates, both high molecular weight MAP2 (Chang et al, 2003) 
and doublecortin (Gdalyahu et al, 2004). MAP2 functions as a microtubule 
stabilizing protein and is expressed in dendrites mostly in mature neurons 
(Chang et al, 2003). DCX, which is expressed at high levels in the processes of 
developing neurons, is required for neuronal migration and DCX-/- mice exhibit 
lamination defects in the hippocampus (Corbo et al, 2002). It is unknown 
however, whether regulation of MAP2 and DCX by JNK1 directly controls 
microtubules. Recently, SCG10, a member of the stathmin family that is also 
known to regulate microtubules, was identified as a JNK1 target in neuronal 
processes (Tararuk et al, 2006). Phosphorylation of SCG10 is reduced in JNK1-/-
cortex and JNK inhibition prevents SCG10 phosphorylation, reduces microtubule 
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polymerization and affects the morphology of processes of cortical neurons in 
vitro (Tararuk et al, 2006). Several studies showed that in degenerating 
processes, microtubules form beaded structures that accumulate in the same 
regions where swellings appear. These changes are likely due to spatial 
rearrangements rather than differences in the total levels of tubulin, since our 
results show that the total levels of tubulin monomers are not affected during 
early stages of process degeneration. While microtubules are essential for the 
maintaining of cell shape and for axoplasmic transport, it remains open if 
microtubule rearrangements play a causal role in the degeneration of processes 
or if it is a secondary event. It would therefore be interesting to further investigate 
if the effects of JNK signaling in our system may be accounted in part by the 
regulation of proteins that control the dynamics of microtubules. JNK may also 
contribute to the degeneration of processes by cross-talking with GTPase 
pathways, which we also find here to be involved in process degeneration. 
Indeed, when acutely over-expressed in oligodendrocytes, p75NTR causes cell 
death by activating the small GTPase Rac, which subsequently activates JNK1 
and JNK3 (Harrington et al, 2002).
JNK is also likely to target transcriptional regulators in our system. We found that 
blocking the JNK or RhoA pathways prevents the transcriptional up-regulation of 
Galectin-1, suggesting that a p75NTR/JNK-RhoA pathway also controls proteins 
involved in the regulation of gene expression. Several transcription factors were 
previously found to be targets of JNK, such as c-Jun, c-fos and Jun-D (Davis, 
2000). It is thus possible that JNK phosphorylates some of these factors to 
mediate the transcriptional up-regulation of Galectin-1. However, it remains 
puzzling that at the time when Galectin-1 mRNA levels were up-regulated, there 
was no detectable JNK activity in the cell body. One explanation for this is that 
after its activation in processes, a JNK target might be transported towards the 
cell body to act on DNA. Alternatively, JNK could be activated directly by p75NTR
in the cell body but the levels of JNK activity, or the number of JNK molecules 
required for controlling gene expression, may be too low to be detected by 
immunostaining.
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Our results suggest that the degeneration of processes can also be influenced to 
some degree by mitochondrial activity and by the availability of signaling second 
messengers, such as calcium and ATP. Mitochondria remained distributed along 
processes even during advance stages of their degeneration. They were labeled 
with Mitotracker-Orange and their compact morphology was characteristic of 
highly active mitochondria that has been correlated with increased production of 
ATP and ROS (Li et al, 2004). Treatment with EGTA could modestly delay the 
degeneration of processes, while creatine and sodium pyruvate precipitated 
degeneration. It remains to be tested whether these factors have an essential 
role in process degeneration or simply affect the rate of degeneration. A recent 
study by Wang et al (2005) showed that Wallerian degeneration could be 
prevented by treatment with NAD or sodium pyruvate. The authors examined the 
levels of ATP and NAD in DRG axons and showed a rapid decrease after 
axotomy (Wang et al, 2005). The differences between their study and ours may 
be accounted by the use of different cellular systems. In our model, the 
degeneration of processes is triggered by the activation of p75NTR, while in their 
case it is caused by severing the axons. At present, RhoA is the only molecule to 
our knowledge shown to be activated after axotomy (Dubreuil et al, 2003; 
Madura et al, 2004; Yamagishi et al, 2005), and we also found its activity 
increased in tau::p75NTR neurons. It would be interesting to test whether the Rho 
pathway has an effect on the regulation of mitochondrial and of metabolic activity 
within processes. Another possibility is that the drop in ATP and in NAD levels 
reported by Wang and collegues are not due to halted axonal metabolism, but to 
the rapid leak of ATP, NAD and other factors, outside the axoplasm. This 
possibility could be tested by examining the levels of ATP and NAD in 
sympathetic neurons deprived of trophic support, as the degeneration of these 
cells is not caused by mechanical insult. 
3.2.3) Galectin-1 as a novel signaling target and interactor of p75NTR
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Our results show that Galectin-1 expression is positively controlled by p75NTR via 
the JNK and RhoA pathways. Since inhibition of either the JNK or Rho pathways 
had similar effects in preventing the up-regulation of Galectin-1 mRNA, this 
supports the idea that these pathways cross-talk. It would be interesting to 
examine if the Galectin-1 gene contains regulatory sequences for transcription 
factors known to act downstream of these pathways. We also, found that 
Galectin-1 binds to p75NTR, and interfering with Galectin-1 using a soluble p75NTR
protein prevented degeneration of tau::p75NTR neurons. These results suggested 
that the action of Galectin-1 can take place from outside of the cells. Once 
translated, Galectin-1 can be transported to different compartments within the 
neuron or externalize. Exactly how Galectins leave the cell is still unclear as 
these proteins lack a classical secretory signal (for review see Barondes et al, 
1994). Muscle cells for example, externalize somehow Galectin-1 that binds to 
laminin in the basement membrane (Cooper and Barondes, 1990). This in turn 
diminishes attachment of differentiating myoblasts to laminin, presumably by 
preventing laminin-integrin interactions, and it seems to be necessary for their 
division and fusion into myofibres (Cooper et al, 1991). A recent study indicates 
that the externalization of Galectin-1 depends on its ability to bind to ?-
galactosides (Seelenmeyer et al, 2005). When over-expressed in CHO cells, 
Galectin-1 was detected at the cell surface and in the medium, and this 
localization was prevented by mutating its CRD (Seelenmeyer et al, 2005). 
Galectin-1 can also be externalized if expressed in yeast cells (Cleves et al, 
1996), suggesting that the mechanisms responsible for its externalization are 
conserved among species. 
Interestingly, Galectins were also shown to localize to specific regions of cell 
membranes such as lipid rafts (Delacour et al, 2005), which are specialized 
detergents-resistant membrane domains enriched in certain proteins and in the 
lipid cholesterol (Simons and Ikonen, 1997). Many functions have been attributed 
to lipid rafts, such as cholesterol transport, endocytosis and signal transduction, 
and a number of receptors were shown to accumulate in there (Paratcha and 
Ibanez, 2002). Interestingly, Delacour et al (2005) recently reported that Galectin-
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4 localizes to lipid rafts in HT-29 cells. Treatment with an inhibitor of glycosylation 
prevented the localization to lipid rafts of Galectin-4 as well as of a number of 
other raft-associated proteins. A similar result was obtained by depletion of 
Galectin-4 by RNA interference, suggesting that a lectin-based mechanism 
mediated by Galectins is responsible for the transport of glycoproteins to specific 
membrane domains in polarized cells (Delacour et al, 2005). One such protein 
could be p75NTR, which like many cell surface proteins is glycosylated (Baldwin 
and Shooter, 1995). Glycosylation is an enzymatic process that occurs both co- 
and post-translationally, and is essential for the proper folding, stability, transport 
and function of a large number of secreted and membrane bound proteins. There 
are two types of glycosylation, N- and O-linked. N-linked oligosaccharides are 
added to an asparagine residue occurring in the tripeptide sequence Asn-X-Ser
or Asn-X-Thr, where X could be any amino acid except Pro, as the polypeptide 
chain translocates into the lumen of the ER. The glycoprotein formed is 
immediately subjected to further modifications by trimming of some of the sugar 
residues in the ER. After its transport into the Golgi apparatus, the protein can be 
O-linked glycosylated by the addition of N-acetyl-galactosamine to serine or 
threonine residues followed by other carbohydrates, such as galactose and sialic
acid. Because of a large number of different oligosaccharide combinations are 
possible during glycosylation, a protein can be decorated by different sugars, 
allowing cells to diversify the localization, life-time and functions of proteins. 
Putative sites for both N- and O- glycosylation exist in the extracellular domain of 
p75NTR, between the transmembrane region and the first cystein rich domain 
(Baldwin and Shooter, 1995). Breuza et al (2002) investigated whether 
glycosylation of p75NTR was necessary for its transport and cellular localization in 
MDCK cells, by over-expressing different p75NTR mutant constructs. MDCK cells 
are polarized cells having two distinct membrane domains, the basolateral and 
the apical domains, and when expressed in these cells, p75NTR localizes to the 
surface of the apical membrane (Monlauzeur et al, 1998; Breuza et al, 2002). 
Interestingly, it was found that O- but not N-linked glycosylation is essential for 
the correct targeting of p75NTR to the apical membrane. Since lectin proteins are 
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known to recognize specific sugar residues in glycoproteins, the authors 
suggested that a lectin might help p75NTR be transported to the cell surface 
(Breuza et al, 2002). In a more recent study, Galectin-3 was identified as a 
protein that binds to p75NTR directly and that helps its localization to the apical 
membrane (Delacour et al, 2006). It is possible that Galectin-1 in neurons plays a 
similar role to that of Galectin-3 in epithelial cells, aiding p75NTR intracellular 
transport to specific membrane regions. 
In addition to participating in the transport of p75NTR to the cell surface, Galectin-
1 may also help the clustering of the receptor. In its reduced form, Galectin-1 
exists mostly as a dimer, having two unbound CRDs (Liu and Rabinovich, 2005; 
Barondes et al, 1994), and may thus facilitate the clustering of p75NTR by cross-
linking receptor subunits. In preliminary experiments, we found immunoreactivity 
for Galectin-1 along the processes and in the cell body of non-permeabilized 
neurons, suggesting that Galectin-1 is externalized and associated with 
molecules at the cell surface (data not shown). Unlike p75NTR, the staining for 
Galectin-1 did not exhibit an uneven pattern but was evenly distributed along the 
cell surface. This suggests that Galectin-1 binds not only to p75NTR but also to 
other cell surface receptors. 
Unlike other TNF receptor superfamily members that form trimers upon ligand 
binding, studies reported that p75NTR bound to neurotrophins can occur either as 
a dimer or monomer. At present however, it is debated whether p75NTR activates 
signaling in its monomeric or dimeric form. Examining the crystal structure of 
p75NTR complexed with NGF, He and Garcia (2004) reported that p75NTR in its 
unliganded state exists either as a dimer or as a monomer, but a p75NTR:NGF
complex is composed of an NGF homodimer asymmetrically bound to a single 
p75NTR molecule. Binding of an NGF homodimer prevents monomeric p75NTR
from binding another p75NTR molecule. By contrast, Aurikko et al (2005) recently 
suggested a 2:2 stoichiometry in the NGF:p75NTR complex. These different 
conclusions might be due to differences in the p75NTR preparations used. He and 
Garcia (2004) used tunicamycin to inhibit N-glycosylation, and this was previously 
shown to negatively affect of the affinity of p75NTR for NGF in vitro (He and 
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Garcia, 2004). In addition, treatment of PC12 cells with tunicamycin diminishes 
binding of NGF and prevents the elongation of processes (Baribault and Neet, 
1985). As most cell surface receptors isolated from the mammalian nervous 
system typically exist as glycoproteins (Hoffmann et al, 1995), it is unclear 
whether unglycosylated p75NTR exists under physiological conditions. In the 
future it would be interesting to investigate how Galectins influence 
conformational changes in p75NTR, and if this triggers signaling. 
When testing the killing effects of exogenously-applied Galectin-1 and WGA, we 
also observed that neither of these lectins promoted the internalization of the 
receptor in control neurons. By contrast, both NGF and BDNF promoted the 
internalization of p75NTR from the cell surface of both processes and cell body
(data not shown). Other studies also showed internalization of p75NTR upon 
neurotrophin binding. Bronfman et al (2003) reported that p75NTR was 
internalized with NGF via clathrin-coated pits in PC12 cells. It would be 
interesting to test the prediction that Galectins and WGA promote sustained 
signaling via p75NTR by preventing its internalization. If this were the case, then 
neurotrophin treatment should diminish signaling via p75NTR by promoting its 
removal from the cell surface. In line with this prediction, we found that treatment 
of control neurons with neurotrophins promoted branching of processes. 
However, neurotrophins failed to prevent the degeneration of processes in 
tau::p75NTR neurons (data not shown). One possible explanation for this is that 
the expression levels of p75NTR in tau::p75NTR neurons are sufficiently high so 
that the action and localization of the receptor become independent of 
neurotrophin binding. The different outcome of binding of lectins or neurotrophins 
to p75NTR are likely due to the different regions to which these ligands bind to. 
While all four mammalian neurotrophins bind to the cysteine-rich domains 
(Dechant and Barde, 2002), Galectins and WGA are likely to bind to the 
juxtamembrane extracellular domain which contains the N- and O-glycosylation 
sites (Baldwin and Shooter, 1995). 
3.2.4) Killing function of Galectin-1 
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Our experiments using recombinant Galectin-1 showed that this lectin causes 
degeneration of control neurons. A killing role for Galectin-1 was first described in 
non-neuronal cells by Perillo et al (1995) using T cells. Galectin-1 is expressed 
by stromal cells in human thymus and lymph nodes, and is present at sites where 
T cells undergo programmed cell death during their development (Perillo et al, 
1995). Interestingly, while exogenously applied Galectin-1 caused the death of 
activated human T cells and human T leukaemia cell lines, it did not kill resting T 
cells. Other Galectins were also shown to cause cell death. Like Galectin-1, 
Galectin-2 (Sturm et al, 2004), Galectin-9 (Wada et al, 1997; Kashio et al, 2003) 
and Galectin-3 (Stillman et al, 2006), kill activated T cells. Galectin-4 contributes 
to exacerbation of intestinal inflammation by killing activated intestinal T cells 
(Hokama et al, 2004). Galectin-7 (Bernerd et al, 1999; Kuwabara et al, 2002) and 
Galectin-12 (Hotta et al, 2001) were also shown to cause cell death, but unlike 
Galectin-1,-2-,9 and -3, Galectin-7 and -12 killing effects required their 
intracellular localization. It was suggested that certain tumors can escape the 
immune response by secreting Galectins that kill activated T cells. Galectins are 
often expressed at high levels by cancerous cells, and the levels of expression 
correlate with the aggressiveness of a number of tumors (see review by Liu and 
Rabinovich, 2005). Galectins may also help tumor cells proliferating by 
stimulating Ras-mediated mitogenic signaling pathways, and both Galectin-1 and 
Galectin-3 interact with oncogenic Ras and facilitate signaling (Paz et al, 2001; 
Elad-Sfadia et al, 2004). 
Previous work by Horie et al (1999) proposed that Galectin-1 enhances the 
growth of regenerating axons after axotomy. In their experiments, the growth of 
processes was assessed from DRG explants that after dissection, retained part 
of their central and peripheral projections. Addition of recombinant Galectin-1 
increased the number of regenerating processes (Horie et al, 2004). These 
experiments however, were performed with Galectin-1 in its oxidized form. 
Importantly, Galectins contain 6 cystein residues that do not form disulfide 
bridges, and can thus be rapidly oxidized in solution. In its oxidized form, 
Galectins loose their ability to bind to ?-galactosides (Lopez-Lucendo et al, 
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2004). Also, the oxidation state of Galectins affects the balance between dimeric 
and monomeric forms, and significant conformational changes likely yield 
different surfaces accessible for binding to different ligands. In our study, we 
found that reduced, but not oxidized Galectin-1 kills processes. In addition, co-
treatment with lactose prevented the killing effect of reduced Galectin-1, 
indicating that the oxidation status of Galectins determines the protein’s function. 
It is therefore unclear how oxidized Galectin-1 increases the number of growing 
processes from DRG explants (Horie et al, 1999). One possibility is that this 
effect was rather indirect, as recent work by the same authors showed that 
oxidized Galectin-1 acts on macrophages to recruit these cells after nerve injury 
(Horie et al, 2004). Thus, while Galectin-1 in its oxidized form may function as a 
factor that indirectly regulates nerve regeneration by acting on macrophages, the 
function of Galectin-1 in its reduced form as well as its cellular target/s remain 
unknown.
The killing action of Galectin-1 kills in our system did not require p75NTR, as 
processes of ES cell-derived neurons lacking both p75NTR alleles were also 
eliminated. Galectin-1 may thus act by binding to other cell surface receptors, 
such as various members of the p75NTR family. Galectin-1 was also shown to 
bind to integrin receptors (Moiseeva et al, 2003). Future experiments will 
investigate the expression of these in different neurons. Indeed, it is of interest 
that while ES cell-derived neurons and cortical neurons were vulnerable to 
Galectin-1, hippocampal neurons were not (data no shown). This neuronal type 
specificity may be due to the differential expression of cell surface molecules 
and/or of interactor proteins that couple extracellular factors to intracellular 
signaling. Another possibility is that Galectin-1 mediates its effects indirectly, by 
interfering with the adhesion of neuronal processes to substrate. For example, 
Galectin-1 can bind to extracellular matrix components such as laminin and 
fibronectin. This might produce changes in signaling through receptors involved 
in cell adhesion that could also trigger a degeneration process. Indeed, such a 
mechanism has been shown for Galectin-8 on several immortalized cell lines 
(Hadari et al, 2000; Levy et al, 2001; Zick et al, 2004). Whether cortical neurons 
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are more sensitive than hippocampal neurons to contact deprivation with their 
substrate is unknown at this point. 
3.2.5) Functional specificity of Galectin-1 and Galectin-3
Structural differences exist among Galectin-family members. Galectins 
1,2,5,7,10,11,13,14 and 15 have only one CRD, while Galectins 4,6,8,9 and 12 
have two CRDs connected by a ~70 amino acids linker region. The prevailing 
idea is that one-CRD Galectins form dimers, while two-CRD Galectins exist as 
monomers (Liu and Rabinovich, 2005). Galectin-3 has one CRD but differs from 
all other Galectin-family members in that it contains unique short stretches of 
amino acids tandem repeats in its CRD (Cooper, 2002). Since Galectins can 
form both bivalent and multivalent binding sites, they have the potential to cross-
link cell surface glycoconjugates, leading to the formation of clusters or lattices. 
They also mediate cell-cell or cell-extracellular matrix interactions. 
We compared the effects of Galectin-1 with that of Galectin-3 and found that 
unlike Galectin-1, Galectin-3 did not kill control neurons. Galectin-1 and Galectin-
3 are the most widely expressed members of the Galectin family in the organism. 
Their expression can be either segregated or overlapping in different organs (see 
review by Rabinovich et al, 2002; Hsu et al, 2004). Previous studies have 
compared the functions of these Galectins in other systems and reported on a 
number of differences and similarities. For example, both Galectins can localize 
to the nucleus and were ascribed functions in RNA processing (Patterson et al, 
2004). Galectin-1 can promote the attachment of the HIV virus to cells while 
Galectin-3 prevents this Galectin-1-mediated attachment (Ouellet et al, 2005). 
Only galectin-3, but not Galectin-1, can protect cells from nitric oxide-induced 
programmed cell death when expressed intracellulary (Song et al, 2002). This 
protective effect was suggested to stem from the fact that Galectin-3 shares 
sequence homology with Bcl2, and might interfere with the action of pro-
apoptotic Bcl2 members (Akahani et al, 1997). Relevant to our study are 
experiments showing that both Galectin-1 and Galectin-3 cause the death of T 
cells in a carbohydrate binding-dependent manner (Perillo et al, 1995; Fukumori 
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et al, 2003). However, the killing effects of these two Galectins are not 
redundant, and they are mediated by binding to different cell surface receptors 
(Stillman et al, 2006). Galectin-1 causes T cell death by binding to CD7 and does 
not bind to the receptor for transferring CD71, while conversely, Galectin-3 does 
not bind to CD7 and causes T cell death by binding to CD71 (Stillman et al, 
2006). Binding of Galectin-1 and Galectin-3 to CD7 and CD71 respectively, 
induces clustering of these receptors (Stillman et al, 2006). Thus, it is possible 
that neurons in our system express receptors for Galectin-1, but not for Galectin-
3, and that this is why they differ in their vulnerability towards these different 
lectins.
3.2.6) Expression and function of Galectin-1 in vivo
At present, little is known about the functions of Galectins in the nervous system. 
Using a well established in vivo model of cholinergic neuron degeneration, we 
find here that Galectin-1 expression is up-regulated by excitotoxicity. We focused 
on cholinergic neurons of the medial septum, a structure of the basal forebrain 
that contains large numbers of these cells (for review see Colom, 2006). Basal 
forebrain cholinergic neurons are important for cognitive functions including 
memory and learning, and those located in the medial septum project axons that 
innervate the hippocampus and thalamus. Importantly, these cells degenerate 
early on during Alzheimer’s disease, and it is generally thought that part of the 
cognitive decline in affected patients is due to the loss of cholinergic transmission 
(Whitehouse et al, 1981). Interestingly, unlike most neurons residing in other 
regions of the adult nervous system, cholinergic neurons of the basal forebrain 
continue expressing p75NTR throughout life, and are therefore a suitable system 
to study the biology of this receptor in adult neurons. It appears that p75NTR is 
involved in the survival of these cells, since increased numbers of cholinergic 
neurons were found in different animals carrying mutations in the p75NTR gene 
(Naumann et al, 2002). It remains open however, whether p75NTR controls only 
the survival of these cells, or if it is also involved in other neuronal functions, such 
as for example synaptic transmission. 
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We were encouraged to focus on this system by a previous study reporting on 
the increase in p75NTR levels in the medial septum after injection of kainic acid 
(Oh et al, 2000). Kainic acid is a glutamate receptor agonist and its injection 
caused an up-regulation of p75NTR immunoreactivity both in the cell bodies and in 
processes of cholinergic neurons. Similar to our results, excitotoxicity led to the 
loss of cholinergic neurons within 24 hours. The authors also showed that 
interfering with p75NTR using an antibody that somehow blocks its function 
prevented cholinergic neuron degeneration (Oh et al, 2000). Together with the 
increased number of cholinergic neurons detected in p75NTR-deficient animals, 
these results suggest that the up-regulation of p75NTR triggers the degeneration 
cascade in these cells. While kainic acid is an AMPA receptor agonist, we 
obtained similar results using IBO, which is an NMDA receptor agonist. The 
mechanisms linking glutamate signaling to p75NTR are unknown, but it is tempting 
to speculate that different forms of excitotoxicity might lead to the activation of 
the same molecular machinery involved in neuronal degeneration. Importantly, it 
was also shown that the use of inhibitors of protein synthesis prevented 
excitotoxicity (Oh et al, 2000), perhaps because the prevention of Galectin-1 up-
regulation. This is likely to be the case, as our in vivo results revealed that CEP-
1347 prevented IBO-induced Galectin-1 expression and cholinergic neuron 
degeneration. In addition, it has recently been shown that JNK is activated in 
cultured cholinergic neurons isolated from the basal forebrain (Volosin et al, 
2006), and we find here that blocking the JNK pathway with CEP-1347 also 
prevents the up-regulation of Galectin-1 in tau::p75NTR neurons in vitro. In the 
future, similar experiments could be performed in p75NTR deficient mice to directly 
test if p75NTR is required directly for the up-regulation of Galectin-1. 
Our results using Galectin-1 extracellular decoys indicated that this lectin acts as 
an effector of p75NTR-mediated cholinergic neuron degeneration. Interestingly, a 
soluble p75NTR fusion protein was more effective in preventing the degeneration 
of these cells than lactose or a Galetin-1 antibody. It is possible that in addition to 
blocking Galectin-1, the soluble p75NTR fusion protein also prevents binding of 
pro-neurotrophins to p75NTR. Pro-neurotrophins can be up-regulated in the adult 
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nervous system after injury, and they bind to p75NTR with higher affinity than 
mature neurotrophins (Lee et al, 2001; Harrington et al, 2004). In line with this 
idea, a recent report showed that blocking the actions of pro-neurotrophins 
prevents kainic acid-induced degeneration of cholinergic neurons in the medial 
septum (Volosin et al, 2006). 
At present, a killing function of Galectin-1 in the nervous system has not been 
reported. Analysis of mutant mice deficient for the Galectin-1 gene revealed no 
gross abnormalities (Poirier and Robertson, 1993). However, 15 genes have 
been identified to date that encode for different Galectin members. While some of 
them differ structurally (see above), all members have a conserved CRD. Since 
the killing function of Galectin-1 in our system is likely mediated by its binding to 
sugar, it is possible that other Galectins functionally compensate for the absence 
of Galectin-1. A number of experiments using Galectin-1 null animals may reveal 
important insights into the biology of these proteins. For example, if cholinergic 
neurons were still lost upon excitotoxicity, this would speak in favor of gene 
complementation and should encourage the search for other Galectin members 
that may be involved. Importantly, since Galectin-1 interacts with p75NTR and may 
play a role in its transport to the cell surface, it will be crucial to examine if the 
expression of p75NTR is compromised in Galectin-1 null animals. While a role for 
oxidized Galectin-1 in promoting axonal regeneration has been suggested based 
on experiments using Galectin-1 mutants (see below), the degeneration of 
neurons and of their processes in these mutants has not been reported. Based 
on our results, the prediction is that after injury to neurons or their processes, the 
absence of the Galectin-1 gene would result in a reduced spread of 
degeneration.
Interestingly, Galectin-1 expression is up-regulated in the adult nervous system 
after nerve transection. For example, axotomy of the rodent facial nerve, which 
innervates the whiskers and is composed solely of motor axons, leads to a rapid 
up-regulation of Galectin-1 mRNA in facial motoneuron cell bodies (McGraw et 
al, 2004a). Similar observations were made in spinal cord motoneurons after 
axotomy of spinal nerves (McGraw et al, 2004b). Furthermore, increased levels 
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of Galectin-1 protein were detected in sciatic nerve homogenates after axotomy 
(Horie et al, 2004). In addition, injury of the central projection of DRG neurons led 
to an increase in Galectin-1 immunoreactivity in the dorsal horn of the spinal cord 
(McGraw et al, 2005). These results suggest that the up-regulation in Galectin-1 
levels may occur both at the mRNA and protein level, and that Galectin-1 protein 
may localize not only to cell bodies but also along axons. While the up-regulation 
in Galectin-1 mRNA in the cell bodies of motoneurons and DRG neurons 
suggests that Galectin-1 may be synthesized by neurons themselves, the source 
of production of Galectin-1 that is detected in the distal part of cut nerves remains 
unknown. One possibility is that Galectin-1 is delivered to axons by non-neuronal 
cells, such as Schwann cells. These cells can massively up-regulate expression 
of p75NTR after different types of nerve injury and work by Horie et al 
demonstrated Galectin-1 immunoreactivity in Schwann cells distributed along the 
distal part of axotomized nerves. Thus, it is possible that Galectin-1 is up-
regulated after nerve injury, not only by neurons, but also by other cells. 
In the adult PNS, the degeneration of axons after nerve axotomy can be followed 
by the regeneration of new axons that innervate pre-existing targets (Nguyen et 
al, 2002). In the facial nerve, regeneration after axotomy can be assessed 
functionally by monitoring the recovery of whisker movement (Gilad et al, 1996). 
Interestingly, it has been shown that whisker movement recovery is retarded in 
Galectin-1 null mice as compare to wild type (McGraw et al, 2004), and it was 
proposed that Galectin-1 acts as a positive signal for axonal regeneration. 
However, based on the results presented here, we propose the possibility that 
the retardation of functional recovery in the Galectin-1 mutants stems from the 
failure of transected axons to be rapidly eliminated. It will be important to test this 
possibility by examining the number of surviving axons after facial nerve axotomy 
in wild type and Galectin-1 null animals. In line with this idea, we note that axonal 
regeneration is also retarded in Wlds mutant mice, in which the over-expression 
of a mutant protein somehow prevents the degeneration of axons after axotomy 
(see below and Perry et al, 1990; Brown et al, 1991; Chen and Bisby, 1993). 
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Like Galectin-1, the expression of p75NTR was also shown to be rapidly up-
regulated in facial motoneurons after nerve injury (Ferri et la, 1998). Mice 
deficient for p75NTR exhibited faster recovery of whisker movement. This may 
seem contradictory with a role of p75NTR as an activator of process degeneration 
upstream of Galectin-1. However, the initial observation of faster recovery in 
p75NTR mutants has been difficult to reproduce by others. In addition, as p75NTR
can also restrict the growth of processes (Yamashita et al, 1999), one possibility 
is that in the absence of p75NTR, regenerating axons would grow faster towards 
the whisker.
One additional interesting aspect of the role of Galectin-1 in the nervous system 
is that it has been linked with human nervous system pathology. Inclusions 
containing Galectin-1 were found in human spinal motoneurons from ALS 
patients (Kato et al, 2001). Increased expression of p75NTR was detected in 
spinal cord of ALS patients as well as in transgenic mice over-expressing a 
mutant form of human superoxide dismutase-1 (SOD1), which develop ALS-like 
pathology (Lowry et al, 2001; Kust et al, 2003; Turner et al, 2003; Pehar et al, 
2004).  Since the knock-down of p75NTR in SOD1 mice delays the onset of 
motoneuron degeneration (Turner et al, 2003), it would be interesting to test if 
increased levels of Galectin-1 are detected in SOD1 mutants, and if this is 
prevented by knock-down of p75NTR. If this were the case, interfering with 
Galectin-1’s function using extracellular decoys may prove useful to prevent 
neuronal degeneration in ALS-like disease.  
3.2.7) p75NTR, RhoA and process degeneration  
Our proteomic analyses also revealed changes in the expression of several 
proteins linked with the regulation of actin filaments. These changes correlated 
with increased RhoA activity, as well as with defects on actin filaments, and 
inhibition of Rho kinase prevented the degeneration of processes. These results 
are in line with previous in vivo reports implicating the Rho pathway in the 
degeneration of axons. Studies showed that RhoA is activated after spinal cord 
injury (Dubreuil et al, 2003; Madura et al, 2004; Yamagishi et al, 2005). 
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Importantly, this activation was localized to axons and blocking the Rho pathway 
prevented their degeneration. Furthermore, Dubreuil et al (2003) showed that the 
activation of RhoA was dependent on p75NTR expression. The defects we 
observed in actin filaments were not due to changes in the overall actin levels, 
but to spatial re-arrangements. This is in line with the role of RhoA in controlling 
the polymerization state of actin, typically by rigidifying actin filaments (Jaffe and 
Hall, 2005). In future experiments, it will be interesting to investigate if the 
changes we observed in the distribution of actin filaments are also detected in 
axons after injury in vivo. 
Previous studies suggested that the beading and the fragmentation of 
microtubules are the earliest events affecting the cytoskeleton of degenerating 
processes (Watts et al, 2003; Zhai et al, 2003). However, the integrity of 
microtubules was compared to that of neurofilaments and less attention was paid 
to actin filaments. By contrast, we detected defects in actin filaments 24 hours 
before the microtubules became beaded. We do not know how p75NTR might 
control actin filaments and microtubules. One possibility is that p75NTR controls 
actin filaments via the RhoA/Rho kinase pathway and microtubules through the 
JNK pathway. Actin rearrangements could contribute to process degeneration in 
several ways. Actin filaments are highly enriched in the distal regions of growth 
cone filopodia and thin branches, and are highly dynamic structures that can be 
rapidly rearranged (Dent and Gertler, 2003). One possibility is that they act as 
sensors, detecting the activation of signaling pathways that trigger process 
degeneration. Also, rapid changes in the distribution of actin filaments might 
allow molecules involved in signaling pathways to arrange differently, 
determining the nature of signaling events within a process. In this context, it will 
be interesting to investigate if the activation of RhoA occurs at the regions where 
the beading of actin filaments takes place. 
3.2.8) Control of process branching by p75NTR
We found here that p75NTR controls not only the degeneration of processes but 
also their growth and branching via the JNK and RhoA pathways. It is now well 
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established that activated Rho has ‘negative’ effects such as the retraction of 
processes in neuroblastoma cells  (Jalink et al, 1994, Kozma et al, 1997), the 
inhibition process formation in cultured neurons (Bito et al, 2000), and the 
retraction of dendritic branches in cultured hippocampal neurons (Nakayama et 
al, 2000; Wong et al, 2000). The RhoA pathway also mediates the inhibitory 
effects of the myelin-associated molecules Nogo, Mag and Ompg on axonal 
elongation (He and Koprivica, 2004). Interestingly, inhibition of p190RhoGAP, a 
negative regulator for RhoA in Drosophila, results in retraction of mushroom body 
axons (Billuart et al, 2001), suggesting that neurons may have mechanisms that 
actively repress the RhoA pathway. On the other hand, the role of JNK in 
process branching is at present less clear. One possibility is that JNK affects 
branching by targeting components of the cytoskeleton, such as microtubule 
associated proteins (Chang et al, 2003). Treatment with JNK and Rho signaling 
inhibitors promoted growth and branching in tau::p75NTR and in control neurons. 
In addition, we found that p75NTR-/- neurons develop more processes than 
control neurons, and that treatment with neurotrophins can promote process 
branching in control neurons. These experiments suggest that p75NTR controls 
the growth and the survival of processes by the same signaling pathways. It is 
interesting that while neurotrophins affect branching of control processes, they 
can not interfere with their degeneration. It is likely that since p75NTR is expressed 
at higher levels in tau::p75NTR as compare with control neurons, its actions may 
become independent of neurotrophin ligand binding. This is in line with our 
results using deletion construct of p75NTR lacking the extracellular domain. 
What then determines whether a process stops branching or degenerates? One 
possibility is that this depends on the extent of activation of theses pathways. For 
example, when JNK and RhoA reach a certain level of activation, branching is 
arrested, but if the activation levels are higher or last for longer periods, then the 
process degenerates. These mechanisms could serve a role during the time of 
developmental process elimination. For example, several neurons that elongate 
long axons in development express p75NTR. During their elongation, the activity 
of a p75NTR/JNK-RhoA mechanism would prevent axons from extending 
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branches towards inappropriate intermediate targets. In the case that an axon 
has miss-targeted a branch towards an ectopic location, increased signaling via 
p75NTR/JNK-RhoA would lead to the degeneration of this branch. 
We also cannot exclude the possibility that in addition to JNK and RhoA, other 
signaling molecules are recruited by p75NTR, and that some of them mediate only 
branching inhibition or degeneration. A number of proteins previously identified to 
act as scaffolds linking p75NTR to intracellular messengers might be involved, and 
they include caveolin-1 (Bilderback et al, 1997), Bex3/NADE (Mukai et al, 2003), 
TRAF6 (Khursigara et al, 1999; Ye et al, 1999), and the zinc-finger domain 
containing proteins NRIF1/2 (Casademunt et al, 1999) and SC-1 (Chittka and 
Chao, 1999). Other p75NTR intracellular interactors include the MAGE homology 
domain members NRAGE (Salehi et al, 2000) and necdin (Tcherpakov et al, 
2002), and these seem to be involved in the control of programmed cell death. 
p75NTR can also recruit proteins with intrinsic catalyitic activity including the 
serine–threonine kinases IRAK (Mamidipudi et al, 2002) and RIP2 (Khursigara et 
al, 2001) that control interleukin and NF-?B signaling, and the protein tyrosine 
phosphatase FAP-1 (Irie et al, 1999). p75NTR signaling has also been shown to 
induce sphyngomyelinase activity, which leads to the production of ceramide, a 
lipid involved in the regulation of cell death (Dobrowsky et al, 1994; Brann et al, 
2002). Finally, p75NTR is also known to activate the transcription factor NF-?B in 
Schwann cells (Carter et al, 1996). This transcription factor has well established 
roles in promoting cell survival, and a recent study has linked it with the control of 
process branching (Gutierrez et al, 2005). 
3.2.9) Comparison with other models of process degeneration 
To gain insights into the cellular mechanism underlying process degeneration, it 
is useful to compare the in vitro system used here with other models. In 
vertebrates, the most commonly used in vitro model of process degeneration is 
the culture of chick or rodent DRG explants. After plating, axons are allowed to 
grow radially from the explant, and then they are mechanically injured by cutting 
them (for review see Raff et al, 2002). Axonal material then accumulates in the 
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axon stumps indicating that axonal transport was affected, and components of 
the cytoskeleton including microtubules and neurofilaments are broken. After a 
lagging period, axons start to appear unhealthy at the ultrastructural level and 
develop irregular swellings along the entire process. Many axonal components 
accumulate at these swellings and the axon subsequently fragments. The 
direction of degeneration usually starts at the two axon stumps generated by the 
cut, and progresses away from them. This process lasts for 24 to 48 hours 
between the time of axotomy and the final fragmentation. This series of events 
were initially described by Waller (Waller, 1850) and are referred to as Wallerian 
degeneration (for review see Raff et al, 2002). Interestingly, Wallerian-like 
degeneration is also observed when cultured sympathetic neurons are deprived 
of NGF, which is essential to maintain their survival (see for example Koike et al, 
1989).
In vivo, the elimination of processes occurs by at least two different cellular 
mechanisms. Small scale elimination of axonal and dendritic branches occurs by 
retractions, in which branches are swelled back and fuse with the main process. 
This takes place in development during the reduction of poly-innervated 
synapses, and the best known example is the neuromuscular junction (for review 
see Luo and O’leary, 2005). The neuromuscular junction in a muscle fiber is 
initially innervated by axon branches from different motoneurons. Axons 
innervating the same fiber start a competition process that involves synaptic 
activity, in which the axon exhibiting a higher degree of correlated activity 
remains innervating the junction, while others retract their branches (Balice-
Gordon and Lichtman 1994). Branch retractions also occur in the mammalian 
CNS during the formation of eye-specific connections (Luo and O’leary, 2005). 
Retinal ganglion cells project axonal branches towards the dorsal lateral 
geniculate nucleus (dLGN) in the midbrain, and neurons in the dLGN project 
axons to the V1 area of the neocortex.  Initially, branches from the two eyes form 
overlapping arborizations in the dLGN, but as development progresses, these 
arborizations are reduced by branch retractions, until forming individual eye-
specific domains. The same process occurs to the geniculocortical projections 
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that input into the V1 area, and like in the neuromuscular junction, these events 
are controlled electrical activity (Lichtman and Sanes, 2003). In contrast to small-
scale retractions, large-scale elimination of long processes occurs by a different 
cellular mechanism, in which processes degenerate. Degeneration is first 
evidenced by the formation of swellings along the processes and is followed by a 
series of events similar to those described in our system, as well as in models of 
Wallerian degeneration in vitro. In all cases, the regions between the swellings 
thin down and fragment, and the process appears as a dotted line. 
In the developing mammalian brain, large-scale process degeneration has been 
described for layer 5 neurons of the neocortex (O'Leary and Koester, 1993). 
These cells initially project a long axon with branches that input into visual and 
motor cortical areas and into subcortical areas including midbrain, hindbrain and 
spinal cord. By early postnatal days, some branches degenerate depending on 
the functional specification of each neuron (O'Leary and Koester, 1993). Cortical 
neurons involved in motor control eliminate their projections towards visual areas 
and retain their more caudal projections, while neurons involved in the 
processing of visual information retain their projection to visual areas and 
eliminate their projections to motor areas (O'Leary and Terashima, 1988).
Through this mechanism neurons eliminate more than 50% of their original 
projections and form adult topographic maps that relate to the spatial 
organization of the parental neurons. Large-scale degeneration was also 
described for retinal ganglion axons that input into the mouse superior colliculus 
or chick optic tectum. When reaching the superior colliculus, axons overshoot 
their final termination areas and form an excessive number of small branches. 
During post-natal days in the mouse, these branches degenerate and only those 
located at the termination area are retained (McLaughlin et al, 2003). It is now 
well established that the formation of these topographic maps is mediated by the 
ephrin signaling system (Luo and O’Leary, 2003). However, the degeneration of 
processes seems to depend mostly on neuronal activity and like with the dLGN, 
correlated activity prevents degeneration. Large-scale elimination of neuronal 
processes also occurs in invertebrates. As they undergo metamorphosis, 
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neurons of the Drosophila mushroom body eliminate specific axonal and 
dendritic branches and they elongate new ones after metamorphosis (Watts et al, 
2003). By doing so, these neurons can serve different functions in larval stages 
and in adult life. 
In the lesioned adult nervous system, various pathological conditions also lead to 
large scale process degeneration. These include amyotrophic lateral sclerosis, 
spinal muscular atrophy, peripheral neuropathies, and AIDS (for review see 
Coleman, 2005). At present, it is not known what triggers the degeneration of 
processes in most of these neuropathies, and it would be important to investigate 
if a molecular mechanism is shared with processes degenerating in vitro.
Process degeneration may also be central to neurodegenerative diseases. 
Widespread loss of processes is observed in Alzheimer’s, Parkinson’s, 
Huntington’s and prion diseases (Coleman, 2005). Because most of the analyses 
were performed in post-mortem brains, it is difficult to determine the precise time 
at which processes degenerated. Thus, it is unclear whether process 
degeneration represented a key early event contributing to the first symptoms of 
these diseases, or if it is a secondary accompanying event. It appears however 
that in many neuropathies and neurodegenerative diseases the degeneration of 
processes precedes the death of cell bodies. Important insights came from 
animal models. For instance, accumulation of Huntingtin protein and of amyloid 
deposits in mouse models of Hungtington’s disease and Alzheimer’s disease, 
respectively, were shown to cause the degeneration of axons before the death of 
cell bodies (Li et al, 1999a; Li et al, 1999b Tsai et al, 2004). Thus, interfering with 
the degeneration of processes may represent a useful approach for at least 
preventing the symptoms of some nervous system diseases. 
At present, it remains unclear how many mechanisms participate in the 
degeneration of neuronal processes, and if it is likely that a process similar to 
programmed cell death may be central to all of them. We note however that in 
our system, the morphology of degenerating tau::75NTR processes resembles that 
of processes undergoing large-scale degeneration in vivo.  This is based on the 
formation of swellings at different lengths along the processes and their 
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subsequent fragmentation into several small fragments. The speed at which 
tau::75NTR processes degenerate is also similar to what has been described for 
axotomized DRG neurons and for NGF-deprived sympathetic neurons in 
Wallerian degeneration models (Zhai et al, 2003). In all cases, 24 to 48 hours 
elapse between the time at which the first swellings form, and the time at which 
processes fragment. Little is know about the timing of large scale degeneration in 
vertebrates in vivo, and it is possible that the speed of degeneration varies 
depending on extrinsic variables such as the extent and type of myelination, the 
molecular and electrical interactions with other cells, the age of the neuron and 
the metabolic state of the cell. The work in Drosophila however (Watts et al, 
2003), indicates that the elimination of processes of mushroom body neurons 
paralleles in its timing to those observed in systems including ours. 
3.2.10) Process degeneration versus cell body death 
Cells undergoing programmed cell death can be observed in real time in vivo, for 
example during the development of the worm C. elegans using Nomarski 
imaging techniques (see for example Hersh et al, 2002). Apoptotic cell bodies 
change light reflection, they shrink and form membrane blebbings that separate 
from the cell body and are referred to as apoptotic bodies (for review by Raff, 
1998). By contrast, it is more challenging to visualize the degeneration of 
processes in vivo, as these are typically close to the limits of resolution of light 
microscopy. Transgenic flies and mice expressing fluorescent proteins in only a 
small number of neurons proved to be useful for imaging processes in their 
natural environment (Feng et al, 2000; Watts et al, 2003). In particular, 
expression of different GFP variants using the Thy1 promoter has helped 
understanding the cellular mechanisms underlying the post-natal process of 
synapse elimination at the mouse neuromuscular junction (see for example 
Lichtman and Sanes et al, 2003). However, while the role of genes predicted to 
play a role in process degeneration starts to be investigated (see for example 
Watts et al, 2003), it remains open whether the elimination of processes 
represents an active series of events. This is in contrast with the extensive 
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knowledge obtained in the last two decades regarding the molecular mechanism 
operating during programmed cell death (see reviews by Ellis and Horwitz, 1991; 
Raff, 1998). Programmed cell death is an active process, as it depends on the 
activation of a molecular machinery that seems to be present in virtually all cells 
of multicellular organisms (Raff, 1998). This includes the caspases, a family of 
cysteine proteases that cleave proteins after aspartic acid residues. Caspases 
are divided into two classes; initiator caspases which are activated first, and 
effector caspases that are activated by initiator capsases and directly cleave 
several substrates. Programmed cell death can be triggered by extrinsic 
mechanisms that involve activation of cell surface receptors such as Fas and 
TNF receptors. The intrinsic pathway involves molecules localized to the 
mitochondria membrane and regulates its permeability. Activation of cell surface 
receptors by pro-apoptotic ligands starts the extrinsic pathway. These receptors 
activate caspase-8 and subsequently the effector caspase-3. Typically, Bcl2 and 
BH3 family members regulate mitochondrial integrity and prevent the release of 
the pro-apoptotic factors cytochrome C and Smac/Diablo, which induce the 
formation of an apoptosome consisting of APAF and caspase-9. When 
complexed, the apoptosome activates the effector caspase-3. Finally, Caspase-3 
is responsible for the execution phase which involves chromatin condensation, 
DNA fragmentation, protein cleavage and membrane permeability. 
Most critical molecules involved in programmed cell death seem to have now 
been identified. However, they seem not to play a crucial role in Wallerian 
degeneration models. Finn et al (2000) reported that caspase activity was not 
detected in degenerating axons, while it was present in dying cell bodies. 
Moreover, broad spectrum caspase inhibitors failed to rescue the degeneration of 
axons while they prevented the death of cell bodies (Finn et al, 2000). These 
results are in line with the experiments reported here, as we find caspase-3 
activity in cell bodies, but not in processes of tau::p75NTR neurons, and pan-
caspase inhibitors can only prevent the death of tau::p75NTR cell bodies.
Similar results were obtained in other studies investigating the participation in 
process degeneration of molecules typically involved in programmed cell death. 
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For example, over-expression of Bcl2, a protein located in the outer 
mitochondrial membrane that protects against programmed cell death (for review 
see Yuan and Horwitz, 2004), prevented the death of motoneuron cell bodies, 
but not the degeneration of motor axons (Sagot et a, 1995). Moreover, over-
expression of Bcl2 can support retinal ganglion cell survival even in the absence 
of processes and of added BDNF (Goldberg et al, 2002). Finally, the BH3 family 
members BAX and BAK also do not seem to play a role in process degeneration. 
Activation of these proteins induces programmed cell death by forming pores in 
the outer mitochondrial membrane, causing the release of cytochrome C into the 
cytoplasm (Yuan and Horvitz, 2004). Studies using BAX and BAK deficient 
animals found that axonal degeneration was not retarded after axotomy as 
compared to wild type animals (Whitmore et al, 2003).
3.2.11) Interfering with process degeneration: The Wlds mutant and the 
ubiquitin-proteasome system  
If the mechanisms involved in programmed cell death do not participate in the 
degeneration of neuronal processes, what do we know about the later? The early 
discovery of a mouse mutant (OLA mouse) helped shedding light on this 
important problem. This was discovered accidentally and was initially thought to 
result from a delayed invasion of macrophages after axotomy. The analysis of 
the mutation in question, now referred to as Wallerian degeneration slow (Wlds),
revealed that it results from a gene triplication leading to a fusion protein that 
consists of the first 70 amino acids of UFD2/E4, a protein involved in 
polyubiquitination, and the full length Nicotinamide mononucleotide 
adenylyltransferase (Nmnat) (Mack et al, 2001). The excitement about the Wlds
mutant stands from the discovery that axonal degeneration is greatly delayed 
after axotomy, both in vivo as well as in cultured mutant neurons (Perry et al, 
1990). Furthermore, axotomized Wlds axons remain electrically active for several 
days after separating them from the cell body and over-expression of Wlds in 
wild type axons protects them from degeneration after axotomy. The most 
striking results regarding the Wlds mutant is that the mutation protects axons in 
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several mouse models of disease. One interesting mutant is the pmn mouse, in 
which a mutation in a tubulin chaperone leads to the improper folding of tubulin 
and results in symptoms that are similar to human spinal muscular atrophy 
(Bommel et al, 2002). Crossing Wlds to pmn homozygous mice rescued the 
degeneration of motor axons and cell bodies and it increased lifespan (Ferri et al, 
2003). The Wlds mutation also prevented the degeneration of axons in two other 
models. Injection of 6-hydroxydopamine into the nigrostriatal pathway of mice 
leads to the loss of dopaminergic axons and is often used as a model of 
Parkinson’s disease. The dopaminergic axons of Wlds mutants were found to be 
less vulnerable to these manipulations (Sajadi et al, 2004). Axon degeneration is 
also observed in mice homozygous for a mutation in the myelin basic protein P0. 
Crossing of these mice to Wlds mice reduced the extent of axon loss and 
promoted motoneuron survival (Samsam et al, 2003). Since the UPS plays a role 
in process degeneration (Watts et al, 2003; Zhai et al, 2003), it was initially 
thought that the protective effect of the Wlds gene product has something to do 
with it. However, the first 70 amino acids of UFD2 do not contain the region of the 
full length protein that is required for polyubiquitination, and it turned out that it is 
only the Nmnat region that protects axons. Araki et al (2004) tested this by over-
expressing different constructs in axotomized axons in vitro and found that 
Nmnat, but not UFD2, protected axons as efficiently as the full length mutant 
protein. One point that remains difficult to explain is that while over-expression of 
Nmnat did not increase the total levels of NAD, exogenously applied NAD could 
protect axons (Araki et al, 2004). Moreover, the localization of the Wlds protein 
remains unclear (Coleman, 2005). One possibility is that Wlds acts on targets 
within the cell body and that these transmit a pro-survival signal to the axons. 
Araki et al (2004) suggested that Sirt1, a protein involved in chromatin 
deacetylation could play such a role. A further investigation of the mechanism of 
action of the Wlds mutation could provide an important venue for preventing 
process degeneration in patients, for example by expressing it after injury. 
So far, the claim that the degeneration of axons is an active process is largely 
based in results obtained with the Wlds mutant (Raff et al, 2002; Coleman, 
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2005). This however, is somehow misleading as Wlds is a fused gene and it is a 
dominant mutation. It is thus possible that its action remains non physiological 
and at present, the Wlds protein has not been shown to directly participate in a 
physiological mechanism required for process degeneration. Interestingly, 
previous studies showed that the normal up-regulation of p75NTR observed in 
Schwann cells after nerve injury, is greatly impaired in the Wlds mutant (Brown et 
al, 1991). This is of interest as it suggests that the Wlds mutation might interfere 
with a molecular mechanism leading to increased expression of p75NTR. Along 
this line, it would be interesting to test if the expression of Wlds prevents 
degeneration in our system, as we now know some of the molecules involved. 
More specifically, it would be important to examine whether the expression 
Galectin-1 and the activity of the JNK and Rho pathways are affected by Wlds. 
In addition to Wlds, the involvement of the ubiquitin-proteasome system (UPS), 
which controls the proteolysis of regulatory or aberrant proteins and is essential 
for cell viability (Ciechanover and Schwartz, 1993), has also been investigated in 
the context of process degeneration. Experiments by Zhai et al (2003) showed 
that pharmacological inhibitors of the UPS delay process degeneration in 
axotomized DRG and NGF-deprived sympathetic neurons. Genetic evidence 
supports a role for the UPS in process degeneration. In Drosophila, the axons of 
? mushroom body neurons (MB), which are required for olfactory learning and 
memory are lost during metamorphosis (Lee et al, 1999). Watts et al (2003) 
demonstrated that the stereotypic degeneration of these axons is prevented in 
flies carrying mutations affecting different components of the UPS machinery. For 
example, homozygous mutants for the first enzyme involved in the UPS cascade, 
the E1 protein, do not degenerate their MB axons (Watts et al, 2003). The 
differentiation of these neurons and their axonal elongation was normal in these 
mutants, suggesting a specific role of the UPS in process degeneration. These 
data are important as they point to the UPS as part of the machinery underlying 
process degeneration. However, it is not known how early in a yet unidentified 
signaling cascade/s the UPS acts. Since it is expected that the degeneration of 
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processes involves widespread protein degradation, it is possible that the action 
of the UPS lies closer to the end of the signaling cascade that triggers 
degeneration.
4. Conclusions and prospects
We exploited here the combination of the use of unlimited quantities of 
homogenous ES cell-derived neurons with the expression of p75NTR from the 
endogenous tau locus. This new cellular system allowed us to perform both, 
experiments based on predictions about the role of molecules known to 
participate in programmed cell death and in p75NTR signaling, as well as 
unbiased analyses based on proteomic comparisons prior to the degeneration of 
processes. The main findings are that processes and cell bodies are eliminated 
by distinct molecular mechanisms, and the identification of a new role for 
Galectin-1 in neuronal degeneration (see working model on Figure.23). 
Our findings also indicate that the degeneration of processes is an active 
process, as it depends on a series of events involving the activity of enzyme 
proteins and of proteins up-regulated by degenerating neurons themselves. It 
therefore appears that neurons may have evolved mechanisms ensuring their 
own elimination when these cells are malfunctioning or damaged. Future 
experiments should investigate how common the molecular mechanisms 
described here are in other models of neuronal degeneration.  Furthermore, our 
results suggest that interfering with these signaling pathways by either blocking 
the JNK or Rho signaling pathways, or by using extracellular decoys against 
Galectin-1, could represent a venue for preventing process degeneration in 
disease.
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5. METHODS
Neuronal differentiation of ES cells  
All ES cell lines were cultured and differentiated into neurons as described in 
Bibel et al. (2004). 
Engineering of mouse ES cell lines 
All genetically modified mouse ES cells were engineered by inserting the 
following cDNAs into the genomic tau loci of J1 wild type ES cell line: The G30 
(tauegfp/egfp) line was generated by K.L..Tucker (University of Heidelberg, 
Germany) and is previously described in Bibel et al. (2004). 
The the tau::p75NTR (taurat p75NTR/eGFP) line was generated by M. Bibel (Novartis, 
Basel). A p75NTR cDNA was targeted to exon 1 of the tau locus. In brief, PmeI 
restriction site followed by an optimized Kozak sequence at the start codon was 
added to p75NTR cDNA and NotI was engineered just after the stop codon. Thus, 
the endogeneous initiation codon of tau as well as the stop codon in front were 
retained and three additional basepairs in between inserted for the Kozak 
sequence. The following primers were used (restriction sites in bold, Kozak 
sequence in italics, start and stop codon underlined): 5`-TCC AGG GTT TAA 
ACC GCC ACC ATG AGG AGG GCA GGT GCT G-3` and 5`-GAT CGC GGC 
CGC TCA CAC TGG GGA TGT GGC AG-3`. The targeting vector for 
homologous recombination in ES cells was constructed by insertion of the 
engineered p75NTR cDNA in the PmeI and NotI site of a plasmid containing Pgk-1
polyadenylation signal, the G418-selectable marker Pgk-Neor and 8.0 kb flanking 
genomic sequence. The linearized targeting vector was electroporated into ES 
cells that were already targeted by a similar strategy with GFP on one allele of 
tau (Tucker et al., 2001) with the difference that the G418-selectable marker Pgk-
Neor was flanked by loxP sites. After electroporation of this line with supercoiled 
plasmids encoding Cre recombinase, a clone that had the neomycin cassette 
deleted was selected (E3). Southern blot analysis of G418-resistant colonies was 
performed as described (Harada et al., 1994). We also tested ES cells with a 
tau+/rat p75NTR genotype and obtained similar results to those obtained with the 
taurat p75NTR/eGFP line (data not shown). The p75NTR -/- ES cell line was engineered 
by C. Anahaim (Biozentrum, University of Basel) and details are described in her 
Ph.D. thesis. 
Staining of ES cell aggregates
Sixteen μm thick cross-sections were rinsed in PBS and incubated for 30 min in 
blocking solution containing 10% serum and 0.2% Triton in PBS (7% Triton was 
used for Oct3/4 staining). Sections were then incubated with primary antibodies 
in blocking solution for 12 hours at 4°C. The following antibodies were used at 
the indicated dilutions: Isl1 (1:500, gift from S Arber), Brn3a (1:10000, gift from E 
Turner), pan-Trk C-14 (1:1000, Santa Cruz), GLAST (1:1000, Chemicon), Oct3/4 
N-19 (1:20000, Santa Cruz), Sox2 AB5770 (1:3000, Chemicon), BrdU (1:1000, 
Sigma), and a p75NTR serum raised against the bacterially expressed cytoplasmic 
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domain of rat p75 (1:1000). The antibodies 40.3A4 (Isl1, 1:1500), 4F2 (Lim1/2, 
1:500), 81.5 C10 (MNR2/Hb9, 1:500), Pax6 (1:1000), 74.5A5 (Nkx2.2, 1:50), 
Nestin (1:10), RC2 (1:10), 50.5A5 (LMX1, 1:50), and Pax7 (1:500) were obtained 
from the Developmental Studies Hybridoma Bank maintained by the University of 
Iowa. In all cases, PBS was substituted for the primary antibodies to test for 
unspecific labelling of secondary antibodies. Sections were rinsed in PBS 
repeatedly and incubated with the following antibodies for 1 hour at room 
temperature: anti-rabbit Rhodamine Red X-conjugated and anti-mouse Cy3 
(1:1000, Jackson), anti-guinea pig (1:1000, gift from S Arber). Secondary 
antibodies were combined with the nuclear stain Hoechst 33342 (10 ?g/ml,
Sigma). Sections were rinsed in PBS and mounted. Sections used for BrdU 
staining were previously incubated in 2 N HCl for 30 min at 37°C, then 
neutralized in 0.1 M sodium tetraborate for 30 min and rinsed in PBS. Pictures 
were collected with a Zeiss Axioplan2 Imaging fluorescent microscope and 
processed with Adobe Photoshop 7.0. 
Chick embryo experiments 
Fertilized chick eggs were incubated at 38.5°C and 80% humidity for 
approximately 42 hours until they reached the 19-21 somite stage. Embryos were 
staged according to Hamburger and Hamilton (Hamburger and Hamilton, 1951). 
Two ml of albumen was removed from the egg and a portion of the upper 
eggshell was opened. To visualize the embryo, drawing ink (Pelikan, A17) was 
dissolved in PBS (16 ?l/ml) and injected under the blastoderm. One neural fold 
was removed over a length of 4 somites at the level of the forelimb bud by 
tearing the tissue with glass needles. RA-treated aggregates were incubated with 
trypsin-EDTA (0.05% trypsin, 0.53 mM EDTA) at 37°C for 10 minutes. ES cell 
aggregates are typically heterogeneous in size and those corresponding 
approximately to the size of the gap to be filled were selected for the implantation 
experiments. RA-untreated aggregates were trypsinized for 6 minutes. After 
incubation with trypsin, one aggregate was transferred with a pipette tip on top of 
the missing portion of the neural tube and implanted manually using tungsten 
needles. By the end of these manipulations, the aggregate had become a lose 
cell aggregate which helped accommodating it in the appropriate position. 
Trypsin-treatment of aggregates was found to be essential as untreated 
aggregates remained compact and did not integrate in the host environment. 
After sealing and incubation for 6 days the embryos were removed from the 
eggs, examined for GFP fluorescence and fixed in 4% paraformaldehyde for 4 
hours. Following incubation in 30% sucrose for 36 hours, they were embedded in 
cryomedium and stored at -80°C for cryosectioning. 
Western blots 
Cells were washed twice in cold PBS, scraped and lysed with RIPA buffer (1% 
NP-40, 0.5% sodium deoxycholate, and 0.1% SDS in PBS) for 30 min. After 
centrifugation at 14.000 rpm the supernatant was stored at -800. Samples were 
resolved on 10% SDS-PAGE gels semi-dry transferred into nitrocellulose. The 
following antibodies were used at the indicated dilution in 1% milk: p75 ICD 
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(Promega, 1:1000) JNK (Santa Cruz, 1:1000), phospho-JNK (Cell Signaling, 
1:2000), phosphor BAD (Upstate, 1:2000); Tuj1 (Babco, 1:2000). Secondary 
antibodies conjugated to HRP were diluted 1:2000 in 1% milk. Blots were 
developed using the enhanced chemiluminescence detection method 
(Amersham).
Pull down assays 
The detection of GTP-bound RhoA (Upstate) was performed following 
manufacturer’s guidelines. For co-immunoprecipitation of Galectin-1, 50 ?g of 
each lysate (prepared as described in the Western Blot section above) was 
mixed with 10 ?l of anti-p75NTR antibody (Promega) and 200 ?l RIPA buffer 
containing 100 ?M DTT, and the mix was incubated for 2 hour at 4°C. Thirty ?l of 
Protein G-Sepharose slurry was the added and the mix was incubated overnight 
at 4°C. After repeated washes in RIPA buffer, the mix was denature and 
processed for Western blot for Galectin-1 as described in the above. 
Transfection of neurons with p75NTR deletion constructs 
The plasmids for over-expression of full length p75NTR, p75NTR ?ECD, and 
p75?DD were previously described in Bibel et al (1998). Four day-old cultures 
were co-transfected for 36-40 hours with 0.16 ?g/ml of pcDNA3 plasmid 
(Invitrogen) for GFP expression, and with 1.6 ?g/ml of one of the p75 plasmids, 
using Lipofectamine 2000 following manufacurer’s instructions (Invitrogen). The 
pcDNA3 plasmid alone was used as control. Cells were then fixed and stained 
for microscopy. 
In vitro treatments of ES cell-derived neurons 
The following reagents were applied to cultures: CEP-1347 (kind gift from Phil 
Barker, McGill University, Canada), fmk-Z-VAD, Y27632, HA1077 (all from 
Calbiochem), creatine, sodium pyruvate, EGTA, lactose, MG-132 (all from 
Sigma), WGA (Vector laboratories). Dimethyl sulfoxide, PBS or bovine serum 
albumin (BSA) were used as controls when appropriate. Recombinant mouse 
Galectin-1 and Galectin-3 (R&D Systems) were diluted in PBS containing 0.1% 
BSA and 50 ?M DTT to avoid oxidation and used immediately upon 
reconstitution. In some experiments, DTT was omitted to enhance oxidation of 
recombinant Galectin-1 and the mix was incubated for 1 hour at 37°C prior to 
adding it to the cultures. For the labeling of mitochondria, Mitotracker-Orange 
(200 nm, Molecular Probes) was added to the cultures for 1 hour prior to fixation. 
The soluble p75NTR protein consists of the entire extracellular domain of p75NTR
fused with an Fc region of a human antibody, and it was previously produced in 
our laboratory (for details see Ph.D. Thesis of David von Shack).
Immunocytochemistry 
Cells grown in nitric acid-treated glass coverslips were washed in PBS, fixed in 
4% paraformaldehyde at 370 for 25 minutes, and washed three times in PBS. 
Cells were then incubated for 30 min in blocking solution containing 10% serum 
and 0.2% Triton in PBS, and for 1 hour with primary antibodies diluted in blocking 
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solution at the indicated concentrations: Tuj1/?III-Tubulin (Babco, 1:2000), active-
Caspase3 (Chemicon, 1:1000), JNK (Santa Cruz, 1:1000), phospho-JNK (Cell 
Signaling, 1:2000), p75ECD (Chemicon, 1:600), p75ICD (Promega, 1:1000), 
CytochromeC (Abcam, 1:1000), GRIP-1 (Cell signaling, 1:2000), NF-M 
(Chemicon, 1:1000). Cells were then washed and incubated with secondary 
antibodies conjugated to Rhodamine, Cy2, or Cy3 (Molecular Probes, 1:1000) for 
1 hour and mounted for microscopy. In some cases the nuclear stain Hoechst 
33342 (Sigma, 10 ?g/ml) was combined with the secondary antibodies. Pictures 
were collected with a Zeiss Axioplan2 Imaging fluorescent microscope and 
processed using Adobe Photoshop 7.0. 
Quantitative analysis of neuronal morphology and degeneration 
Counts were performed manually on randomly-shot pictures of cells double 
labeled with Tuj1 and Hoechst. Neuronal cell body death was assessed by the 
presence of a pyknotic nuclear morphology, characteristic of apoptosis as well as 
the presence of membrane swellings in the cell body. Neuronal processes 
exhibiting signs of beading and swelling were classified as degenerating. To 
quantify the extent of branching, the number of principal processes originating 
from the cell body and having at least two cell body diameters in length were 
determined for each cell in randomly-shot images. Results are representative of 
three independent experiments performed with a minimum sample size of 3 per 
group.  Statistical significance was determined by Student's t-test and data are 
presented as the mean ± standard error. 
Reverse transcription-PCR. Following RNA extraction and reverse 
transcription, a 215 bp fragment of Galectin-1 mRNA was amplified with the 
primers CTCTCGGGTGGAGTCTTCTG (sense) and 
GCCTACACTTCAATCCTCGC (anti-sense). 
Proteomic analysis using difference gel electrophoresis (DIGE) 
All proteomic analysis was performed by the laboratory of J. Voshol, Novartis, 
Basel. On the second day after plating, the cells were washed with cold PBS 
followed by 200 mM sucrose in water, and lysed with DIGE buffer containing 7M 
urea, 2M thiourea, 4% CHAPS, 30 mM Tris-HCl, pH 8.5. 2D-DIGE using minimal 
labeling was performed as previously described27 using triplicate gels of 2 
independent cell preparations. Gels were digitized with the Typhoon imaging 
system (GE Healthcare) and transferred to the Progenesis Discovery V.2005 
software package (Nonlinear Dynamics, UK) for spot detection and matching. 
Matchtables were then exported to Expressionist Pro V.2 (GeneData, 
Switzerland) for statistical analysis. Differentially expressed spots (t-test p<0.05 
and two-fold up- or down regulation) were excised from the gels and identified by 
MALDI-TOF-TOF mass spectrometry. 
Rat experiments 
Sprague Dawley rats between 220-240 grams were anesthetized with isoflurene-
oxygen gas and placed in a stereotaxic frame (TSE Systems, Germany). A 28 
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gauge injection cannula (Plastic One, Roanoke VA, USA) connected to a 
microinfusion pump (CMA, Sweden) via a 0.28 mm ID polythene tubing (SIMS, 
Portex) was filled with PBS or with 0.3 mg/ml ibotenic acid alone or in 
combination with 250 mM lactose or 0.5 mg/ml anti-Galectin-1 affinity purified 
goat antibody (R&D Systems). The cannula was directed towards the MS by 
using the coordinates from the Paxinos and Watson atlas from Bregma, AP: 
+0.7, ML: +0.4, DV: 6 from dura. 0.3 ?l infusions were microinjected over a 5 min 
period and the cannula was left in place for another 5 min to allow for recovery. 
Twenty six hours after operation rats were perfused with 4% PFA, the brain was 
removed, post-fixed in cold 4% PFA for 4 hours, cryoprotected in sucrose 
gradients and frozen for cryosectioning. Twenty ?m thick coronal sections were 
collected onto pre-coated slides, rehydrated in PBS, incubated for 1 hour with 
blocking solution containing 10% normal donkey serum, 0.2% bovine serum 
albumen and 0.3% Triton-X100 in PBS, and then incubated overnight with the 
following antibodies in blocking solution at the indicated concentrations: rabbit 
anti-p75NTR (1:250, Promega); goat anti-Galectin-1 (R&D Systems; RD). Sections 
were repeatedly rinsed in PBS and incubated with species-specific Cy3-
conjugated antibodies (1:1,000; Molecular Probes) combined with Hoechst 
33342 (10 ?g/m, Sigma) in PBS and mounted. Pictures were collected with a 
Zeiss CCD digital camera connected to a Zeiss Axioplan2 Imaging fluorescent 
microscope and processed using Adobe Photoshop 7.0. Cholinergic neuron 
numbers and the presence of processes in each neuron were determined by 
direct counts using a 950 x 325 ?m2 grid corresponding to the medial septum in 
six sections per animal. This area lies directly above an imaginary line traced 
between the top of the anterior commissure traversed by the midline.  Six 
sections were scored per animal. Results are representative of three 
independent experiments performed with a minimum sample size of 3 animals 
per group.  Statistical significance was determined by Student's t-test and data 
are presented as the mean ± standard error. 
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Table 1. Embryos operated in this analysis and integration of donor cells
Legend to Table 1 
Analyses were performed on embryos from 16 independent experiments (9 with RA-
treated ES cells and 7 with RA-untreated ES cells). Operated embryos were initially
observed as whole mount and those showing a GFP signal at the implant region 
(third column) were sectioned. All these embryos contained numerous GFP+ cells in 
several continuous sections, but the number of these varied. GFP+ cells were 
frequently detected in the ventral spinal cord (VSC) extending axons towards the 
periphery (fourth column), and in the DRG (fifth column). In few sections, donor cells
were detected only in the DRG, suggesting that they also migrated along the anterior-
posterior axis. We failed to detect mouse nuclei in embryos that did not exhibit a GFP 
signal (~40%), suggesting that the donor cells did not survive in these animals.
Results are (± s.e.m.) and n represents the number of embryos analyzed.
Legend to Table 2
The number of mouse nuclei was quantified in the spinal cord and in the DRG of 
embryos collected from 8 independent experiments. Results show the percentage (± 
s.e.m.) of Hoechst-stained mouse nuclei that expressed GFP, indicating their neural 
identity.
Legend to Table 3
The analyses were performed on sections from embryos implanted with RA-treated 
or with RA-untreated ES cells (5 independent experiments). Results show 
percentage (± s.e.m.) of GFP+ cells that expressed Lim1/2 throughout the spinal cord
(SC), Hb9 or Isl1 in the ventral spinal cord (VSC), and Brn3a or Isl1 in the DRG.
Number of embryos
operated
Number of embryos
surviving operation
Number of embryosCell type
implanted
% embryos containing% embryos containing GFP+
with GFP+ cells GFP+ cells in DRGcells in VSC with axons
65.5 ± 27.3 (n=24) 59.2 ± 34.5 (n=27)113 101 63RA-treated cells
74.9 ± 27.6 (n=16) 86.1 ± 16.4 (n=19)86 71 56RA-untreated cells
Table 2. Neuronal differentiation of donor cells
% of mouse neurons
in spinal cord
Cell type
implanted
% of mouse neurons
in DRG 
RA-treated cells 78.5 ± 15.3 81.3 ± 5.5
RA-untreated cells 72.8 ± 19.2 65.4 ± 17.1
Table 3. Expression of neural markers by donor cells
Hb9 Isl1 Brn3a in Isl1 in Lim1/2Cell type
implanted in SC in VSC in VSC DRG DRG
RA-treated cells 39.3 ± 10.2 73.6 ± 23.5 80 ± 26.4 0 0
42.8 ± 10.9 15.4 ± 6.4 43.9 ± 36.8 36.7 ± 18.6RA-untreated cells 21.1 ± 4.7
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